0001551152-23-000045 | 10-Q | XBRL Viewer

Supplemental Financial Information

9 Months Ended

Sep. 30, 2023

Supplemental Financial InformationInterest Expense, Net


	Three months ended September 30,				Nine months ended September 30,
(in millions)	2023		2022		2023		2022
Interest expense	$	555	$	560	$	1,660	$	1,664
Interest income	(157)		(63)		(354)		(96)
Interest expense, net	$	398	$	497	$	1,306	$	1,568

Inventories


(in millions)	September 30, 2023		December 31, 2022
Finished goods	$	1,035	$	1,162
Work-in-process	1,690		1,417
Raw materials	1,256		1,000
Inventories	$	3,981	$	3,579

Property and Equipment, Net


(in millions)	September 30, 2023		December 31, 2022
Property and equipment, gross	$	11,374	$	10,986
Accumulated depreciation	(6,440)		(6,051)
Property and equipment, net	$	4,934	$	4,935

Depreciation expense was $196 million for the three months and $565 million for the nine months ended September 30, 2023 and $181 million for the three months and $582 million for the nine months ended September 30, 2022.

Segment Information - Additional Information (Details)	9 Months Ended
Segment Information - Additional Information (Details)	Sep. 30, 2023 segment
Segment Reporting [Abstract]
Number of operating segments	1

Financial Instruments and Fair Value Measures - Debt and Credit Facilities (Details) - USD ($)	1 Months Ended					2 Months Ended	9 Months Ended
	Mar. 31, 2023	Jan. 31, 2023	Jul. 31, 2022	Feb. 28, 2022	Jan. 31, 2022	Feb. 28, 2023	Sep. 30, 2022	Sep. 30, 2023	Jun. 30, 2023	Dec. 31, 2022
Floating rate notes due 2023, refinanced \| Term loan facilities
Debt and Credit Facilities [Line Items]
Repayments of long-term debt		$ 1,000,000,000
2.8% senior notes due 2023 \| Senior notes
Debt and Credit Facilities [Line Items]
Repayments of long-term debt	$ 350,000,000
Stated interest rate (as a percent)	2.80%
Senior Notes Due 2023 At 2.850 Percent \| Senior notes
Debt and Credit Facilities [Line Items]
Stated interest rate (as a percent)								2.85%
Senior Notes Due 2023 At 2.850 Percent \| Term loan facilities
Debt and Credit Facilities [Line Items]
Repayments of long-term debt		$ 1,000,000,000
3.45% senior notes due 2022 \| Senior notes
Debt and Credit Facilities [Line Items]
Repayments of long-term debt					$ 2,900,000,000
Stated interest rate (as a percent)					3.45%
Floating rate notes due 2025 \| Term loan facilities
Debt and Credit Facilities [Line Items]
Repayments of long-term debt				$ 2,000,000,000
Aggregate principal amount outstanding				$ 2,000,000,000
Term loan credit agreement term				5 years
Floating rate notes due 2025, refinanced \| Term loan facilities
Debt and Credit Facilities [Line Items]
Long-term debt obligations, gross				$ 2,000,000,000
3.25% senior notes due 2022 \| Senior notes
Debt and Credit Facilities [Line Items]
Repayments of long-term debt			$ 1,700,000,000
Stated interest rate (as a percent)			3.25%
Senior Notes Due At 3.20 Percent \| Senior notes
Debt and Credit Facilities [Line Items]
Repayments of long-term debt							$ 1,000,000,000
Stated interest rate (as a percent)							3.20%
Revolving Credit Facility
Short-Term Borrowings [Line Items]
Line of Credit Facility, Expiration Period	5 years					5 years
Line of Credit Facility, Maximum Borrowing Capacity						$ 4,000,000,000			$ 5,000,000,000
Long-Term Line of Credit								$ 0		$ 0

Goodwill and Intangible Assets - Goodwill (Details)	9 Months Ended
Goodwill and Intangible Assets - Goodwill (Details)	Sep. 30, 2023 USD ($)
Changes in the carrying amount of goodwill
Balance at the beginning of the period	$ 32,156,000,000
Foreign currency translation adjustments	(65,000,000)
Balance at the end of the period	32,091,000,000
Accumulated goodwill impairment losses
Accumulated goodwill impairment losses	$ 0

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References + Details

Licensing, Acquisitions and Other Arrangements	9 Months Ended
Licensing, Acquisitions and Other Arrangements	Sep. 30, 2023
Licensing, Acquisitions, and Other Arrangements
Licensing, Acquisitions, and Other Arrangements	Licensing, Acquisitions and Other Arrangements Other Licensing & Acquisitions Activity Cash outflows related to acquisitions and investments totaled $670 million for the nine months ended September 30, 2023 and $494 million for the nine months ended September 30, 2022. AbbVie recorded acquired IPR&D and milestones expense of $66 million for the three months and $496 million for the nine months ended September 30, 2023 and $40 million for the three months and $454 million for the nine months ended September 30, 2022. Syndesi Therapeutics SA In February 2022, AbbVie acquired Syndesi Therapeutics SA and its portfolio of novel modulators of the synaptic vesicle protein 2A, including its lead molecule ABBV-552, previously named SDI-118, and accounted for the transaction as an asset acquisition. ABBV-552 is a small molecule, which is being evaluated to target nerve terminals to enhance synaptic efficiency. Under the terms of the agreement, AbbVie made an upfront payment of $130 million which was recorded to acquired IPR&D and milestones expense in the condensed consolidated statement of earnings in the first quarter of 2022. The agreement also includes additional future payments of up to $870 million upon the achievement of certain development, regulatory and commercial milestones. Juvise Pharmaceuticals In June 2022, AbbVie and Laboratories Juvise Pharmaceuticals (Juvise) entered into an asset purchase agreement where Juvise acquired worldwide commercial rights of a mature brand Pylera, which is used for the treatment of peptic ulcers with an infection by the bacterium Helicobacter pylori. The transaction was accounted for as the sale of an asset. Upon completion of the transaction, AbbVie received net cash proceeds of $215 million and recognized a pre-tax gain of $172 million which was recorded in other operating income in the condensed consolidated statement of earnings in the second quarter of 2022. Other Arrangements AbbVie entered into several other arrangements resulting in charges related to upfront payments of $44 million for the three months and $396 million for the nine months ended September 30, 2023 and $40 million for the three months and $262 million for the nine months ended September 30, 2022. Acquired IPR&D and milestones expense also included development milestones of $22 million for the three months and $100 million for the nine months ended September 30, 2023 and $62 million for the nine months ended September 30, 2022. There were no development milestones for the three months ended September 30, 2022.

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Income Taxes (Details) - USD ($) $ in Millions	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Effective tax rate	9.00%	10.00%	20.00%	11.00%
U.S. statutory tax rate	21.00%	21.00%
Potential change in unrecognized tax benefits	$ 620		$ 620

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation Basis of Historical Presentation The unaudited interim condensed consolidated financial statements of AbbVie Inc. (AbbVie or the company) have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the company’s audited consolidated financial statements and notes included in the company’s Annual Report on Form 10-K for the year ended December 31, 2022. It is management’s opinion that these financial statements include all normal and recurring adjustments necessary for a fair presentation of the company’s financial position and operating results. Net revenues and net earnings for any interim period are not necessarily indicative of future or annual results. Certain other reclassifications were made to conform the prior period interim condensed consolidated financial statements to the current period presentation.

Integration and Restructuring Plans (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Allergan integration plan
Restructuring charges
Incurred total cumulative integration charges	$ 2,500		$ 2,500
Charges associated with integration or restructuring plans	60	$ 116	202	$ 329
Restructuring reserve rollforward
Accrued balance beginning of the period			107
Restructuring charges			192
Payments and other adjustments			(258)
Accrued balance end of the period	41		41
Allergan integration plan \| Cost of products sold
Restructuring charges
Charges associated with integration or restructuring plans	20	24	66	81
Allergan integration plan \| Research and development
Restructuring charges
Charges associated with integration or restructuring plans	1	4	2	14
Allergan integration plan \| Selling, general and administrative
Restructuring charges
Charges associated with integration or restructuring plans	39	88	134	234
Other restructuring
Restructuring charges
Charges associated with integration or restructuring plans	10	$ 50	55	$ 143
Restructuring reserve rollforward
Accrued balance beginning of the period			176
Restructuring charges			31
Payments and other adjustments			(64)
Accrued balance end of the period	$ 143		$ 143

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	4,000,000,000	4,000,000,000
Common stock, issued (in shares)	1,822,577,212	1,813,770,294
Treasury Stock, Common, Shares	57,091,177	44,589,000

Equity - Amounts Reclassified Out Of Accumulated Other Comprehensive Loss (Details) - USD ($)
$ in Millions

3 Months Ended

9 Months Ended

Sep. 30, 2023

Sep. 30, 2022

Sep. 30, 2023

Sep. 30, 2022

Significant amounts reclassified out of each component of AOCI

Gains on derivative amount excluded from effectiveness testing

$ 398

$ 497

$ 1,306

$ 1,568

Unrealized Gain (Loss), Foreign Currency Transaction, before Tax

(25)

(36)

(97)

(108)

Tax expense (benefit)

172

448

989

1,139

Total reclassifications, net of tax

(1,778)

(3,949)

(4,041)

(9,363)

Losses (gains) on foreign currency forward exchange contracts

6,485

5,022

14,711

13,244

Pension and post-employment benefits

Significant amounts reclassified out of each component of AOCI

Amortization of actuarial losses and other

^[1]

(2)

(5)

166

Tax benefit

(12)

(36)

Total reclassifications, net of tax

(2)

(5)

130

Cash flow hedging activities

Significant amounts reclassified out of each component of AOCI

Total reclassifications, net of tax

(63)

(53)

Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities

Significant amounts reclassified out of each component of AOCI

Tax expense (benefit)

Total reclassifications, net of tax

(1)

(23)

(63)

(53)

Reclassification out of accumulated other comprehensive loss | Net investment hedges | Net investment hedging activities

Significant amounts reclassified out of each component of AOCI

Gains on derivative amount excluded from effectiveness testing

^[2]

(28)

(29)

(85)

(67)

Tax expense (benefit)

Total reclassifications, net of tax

(22)

(23)

(67)

(53)

Foreign currency forward exchange contracts | Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities

Significant amounts reclassified out of each component of AOCI

Losses (gains) on foreign currency forward exchange contracts

^[3]

(11)

(21)

(67)

(47)

Treasury rate lock agreements | Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities

Significant amounts reclassified out of each component of AOCI

Gains on derivative amount excluded from effectiveness testing

^[2]

(6)

(18)

Cross-currency swap contracts | Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities

Significant amounts reclassified out of each component of AOCI

Unrealized Gain (Loss), Foreign Currency Transaction, before Tax

^[4]

(14)

(6)

Interest rate swap contracts | Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities

Significant amounts reclassified out of each component of AOCI

Gains on derivative amount excluded from effectiveness testing

^[2]

$ 0

$ 3

[1]	(b) Amounts are included in the computation of net periodic benefit cost (see Note 9).
[2]	(a) Amounts are included in interest expense, net (see Note 8)
[3]	(c) Amounts are included in cost of products sold (see Note 8).
[4]	(d) Amounts are included in net foreign exchange loss (see Note 8).

Earnings Per Share

9 Months Ended

Sep. 30, 2023

Earnings Per Share [Abstract]

Earnings Per Share

Earnings Per ShareAbbVie grants certain restricted stock units (RSUs) that are considered to be participating securities. Due to the presence of participating securities, AbbVie calculates earnings per share (EPS) using the more dilutive of the treasury stock or the two-class method. For all periods presented, the two-class method was more dilutive.

The following table summarizes the impact of the two-class method:


	Three months ended September 30,				Nine months ended September 30,
(in millions, except per share data)	2023		2022		2023		2022
Basic EPS
Net earnings attributable to AbbVie Inc.	$	1,778	$	3,949	$	4,041	$	9,363
Earnings allocated to participating securities	11		18		32		43
Earnings available to common shareholders	$	1,767	$	3,931	$	4,009	$	9,320
Weighted-average basic shares outstanding	1,767		1,771		1,768		1,771
Basic earnings per share attributable to AbbVie Inc.	$	1.00	$	2.22	$	2.27	$	5.26

Diluted EPS
Net earnings attributable to AbbVie Inc.	$	1,778	$	3,949	$	4,041	$	9,363
Earnings allocated to participating securities	11		18		32		43
Earnings available to common shareholders	$	1,767	$	3,931	$	4,009	$	9,320
Weighted-average shares of common stock outstanding	1,767		1,771		1,768		1,771
Effect of dilutive securities	4		5		4		6
Weighted-average diluted shares outstanding	1,771		1,776		1,772		1,777
Diluted earnings per share attributable to AbbVie Inc.	$	1.00	$	2.21	$	2.26	$	5.24

Certain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.

Collaborations

9 Months Ended

Sep. 30, 2023

Collaborative Arrangements [Abstract]

Collaborations

The company has ongoing transactions with other entities through collaboration agreements. The following represent the significant collaboration agreements impacting the periods ended September 30, 2023 and 2022.

Collaboration with Janssen Biotech, Inc.

In December 2011, Pharmacyclics, a wholly-owned subsidiary of AbbVie, entered into a worldwide collaboration and license agreement with Janssen Biotech, Inc. and its affiliates (Janssen), one of the Janssen Pharmaceutical companies of Johnson & Johnson, for the joint development and commercialization of Imbruvica, a novel, orally active, selective covalent inhibitor of Bruton’s tyrosine kinase and certain compounds structurally related to Imbruvica, for oncology and other indications, excluding all immune and inflammatory mediated diseases or conditions and all psychiatric or psychological diseases or conditions, in the United States and outside the United States.

The collaboration provides Janssen with an exclusive license to commercialize Imbruvica outside of the United States and co-exclusively with AbbVie in the United States. Both parties are responsible for the development, manufacturing and marketing of any products generated as a result of the collaboration. The collaboration has no set duration or specific expiration date and provides for potential future development, regulatory and approval milestone payments of up to $200 million to AbbVie. The collaboration also includes a cost sharing arrangement for associated collaboration activities. Except in certain cases, Janssen is responsible for approximately 60% of collaboration development costs and AbbVie is responsible for the remaining 40% of collaboration development costs.

In the United States, both parties have co-exclusive rights to commercialize the products; however, AbbVie is the principal in the end-customer product sales. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. Sales of Imbruvica are included in AbbVie's net revenues. Janssen's share of profits is included in AbbVie's cost of products sold. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share.

Outside the United States, Janssen is responsible for and has exclusive rights to commercialize Imbruvica. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. AbbVie's share of profits is included in AbbVie's net revenues. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share.

The following table shows the profit and cost sharing relationship between Janssen and AbbVie:


	Three months ended September 30,				Nine months ended September 30,
(in millions)	2023		2022		2023		2022
United States - Janssen's share of profits (included in cost of products sold)	$	316	$	398	$	925	$	1,210
International - AbbVie's share of profits (included in net revenues)	230		286		711		868
Global - AbbVie's share of other costs (included in respective line items)	59		63		171		196

AbbVie’s receivable from Janssen, included in accounts receivable, net, was $253 million at September 30, 2023 and $295 million at December 31, 2022. AbbVie’s payable to Janssen, included in accounts payable and accrued liabilities, was $308 million at September 30, 2023 and $379 million at December 31, 2022.

Collaboration with Genentech, Inc.

AbbVie and Genentech, Inc. (Genentech), a member of the Roche Group, are parties to a collaboration and license agreement executed in 2007 to jointly research, develop and commercialize human therapeutic products containing BCL-2 inhibitors and certain other compound inhibitors which includes Venclexta, a BCL-2 inhibitor used to treat certain hematological malignancies. AbbVie

shares equally with Genentech all pre-tax profits and losses from the development and commercialization of Venclexta in the United States. AbbVie pays royalties on Venclexta net revenues outside the United States.

AbbVie manufactures and distributes Venclexta globally and is the principal in the end-customer product sales. Sales of Venclexta are included in AbbVie’s net revenues. Genentech’s share of United States profits is included in AbbVie’s cost of products sold. AbbVie records sales and marketing costs associated with the United States collaboration as part of selling, general and administrative (SG&A) expenses and global development costs as part of research and development (R&D) expenses, net of Genentech’s share. Royalties paid for Venclexta revenues outside the United States are also included in AbbVie’s cost of products sold.

The following table shows the profit and cost sharing relationship between Genentech and AbbVie:


	Three months ended September 30,				Nine months ended September 30,
(in millions)	2023		2022		2023		2022
Genentech's share of profits, including royalties (included in cost of products sold)	$	225	$	204	$	641	$	578
AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A)	13		10		32		27
AbbVie's share of development costs (included in R&D)	24		29		82		87

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Statement of Comprehensive Income [Abstract]
Net earnings	$ 1,781	$ 3,952	$ 4,049	$ 9,373
Foreign currency translation adjustments, net of tax expense (benefit) of $(17) for the three months and $(11) for the nine months ended September 30, 2023 and $(11) for the three months and $(30) for the nine months ended September 30, 2022	(457)	(989)	(279)	(2,043)
Net investment hedging activities, net of tax expense (benefit) of $84 for the three months and $26 for the nine months ended September 30, 2023 and $165 for the three months and $348 for the nine months ended September 30, 2022	302	599	89	1,265
Pension and post-employment benefits, net of tax expense (benefit) of $1 for the three months and $11 for the nine months ended September 30, 2023 and $14 for the three months and $35 for the nine months ended September 30, 2022	2	60	38	136
Cash flow hedging activities, net of tax expense (benefit) of $7 for the three months and $(1) for the nine months ended September 30, 2023 and $14 for the three months and $17 for the nine months ended September 30, 2022	52	83	(2)	98
Other comprehensive loss	(101)	(247)	(154)	(544)
Comprehensive income	1,680	3,705	3,895	8,829
Comprehensive income attributable to noncontrolling interest	3	3	8	10
Comprehensive income attributable to AbbVie Inc.	$ 1,677	$ 3,702	$ 3,887	$ 8,819

Post-Employment Benefits (Tables)

9 Months Ended

Sep. 30, 2023

Postemployment Benefits [Abstract]

Summary of net periodic benefit costs relating to the company's defined benefit and other post-employment plans

The following table summarizes net periodic benefit cost relating to the company’s defined benefit and other post-employment plans:


	Defined benefit plans								Other post- employment plans
	Three months ended September 30,				Nine months ended September 30,				Three months ended September 30,				Nine months ended September 30,
(in millions)	2023		2022		2023		2022		2023		2022		2023		2022
Service cost	$	68	$	113	$	203	$	342	$	9	$	13	$	27	$	38
Interest cost	108		74		324		223		9		6		28		18
Expected return on plan assets	(181)		(177)		(543)		(536)		—		—		—		—
Amortization of prior service cost (credit)	—		1		1		2		(9)		(10)		(27)		(29)
Amortization of actuarial loss	4		57		12		173		3		7		9		20
Net periodic benefit cost (credit)	$	(1)	$	68	$	(3)	$	204	$	12	$	16	$	37	$	47

Supplemental Financial Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Interest Expense, Net
Interest expense	$ 555	$ 560	$ 1,660	$ 1,664
Interest income	(157)	(63)	(354)	(96)
Interest expense, net	398	497	1,306	1,568
Inventories
Finished goods	1,035		1,035		$ 1,162
Work-in-process	1,690		1,690		1,417
Raw materials	1,256		1,256		1,000
Inventories	3,981		3,981		3,579
Property and Equipment
Property and equipment, gross	11,374		11,374		10,986
Accumulated depreciation	(6,440)		(6,440)		(6,051)
Property and equipment, net	4,934		4,934		$ 4,935
Depreciation expense	$ 196	$ 181	$ 565	$ 582

Condensed Consolidated Statements of Equity (Unaudited) - USD ($) shares in Millions, $ in Millions	Total	Common stock	Treasury Stock, Common	Additional paid-in capital	Retained earnings	Accumulated other comprehensive loss	Noncontrolling interest
Beginning balance at Dec. 31, 2021	$ 15,436	$ 18	$ (3,143)	$ 18,305	$ 3,127	$ (2,899)	$ 28
Beginning balance (in shares) at Dec. 31, 2021		1,768
Increase (Decrease) in Stockholders' Equity
Net earnings attributable to AbbVie Inc.	9,363	$ 0	0	0	9,363	0	0
Other comprehensive income (loss), net of tax	(544)	0	0	0	0	(544)	0
Dividends declared	(7,537)	0	0	0	(7,537)	0	0
Purchases of treasury stock	(1,483)	$ 0	(1,483)	0	0	0	0
Purchases of treasury stock (in shares)		(10)
Stock-based compensation plans and other	787	$ 0	36	751	0	0	0
Stock-based compensation plans and other (in shares)		10
Change in noncontrolling interest	5	$ 0	0	0	0	0	5
Ending balance at Sep. 30, 2022	16,027	$ 18	(4,590)	19,056	4,953	(3,443)	33
Ending balance (in shares) at Sep. 30, 2022		1,768
Beginning balance at Jun. 30, 2022	14,688	$ 18	(4,591)	18,906	3,516	(3,196)	35
Beginning balance (in shares) at Jun. 30, 2022		1,768
Increase (Decrease) in Stockholders' Equity
Net earnings attributable to AbbVie Inc.	3,949	$ 0	0	0	3,949	0	0
Other comprehensive income (loss), net of tax	(247)	0	0	0	0	(247)	0
Dividends declared	(2,512)	0	0	0	(2,512)	0	0
Purchases of treasury stock	(4)	$ 0	(4)	0	0	0	0
Purchases of treasury stock (in shares)		0
Stock-based compensation plans and other	155	$ 0	5	150	0	0	0
Stock-based compensation plans and other (in shares)		0
Change in noncontrolling interest	(2)	$ 0	0	0	0	0	(2)
Ending balance at Sep. 30, 2022	16,027	$ 18	(4,590)	19,056	4,953	(3,443)	33
Ending balance (in shares) at Sep. 30, 2022		1,768
Beginning balance at Dec. 31, 2022	17,287	$ 18	(4,594)	19,245	4,784	(2,199)	33
Beginning balance (in shares) at Dec. 31, 2022		1,769
Increase (Decrease) in Stockholders' Equity
Net earnings attributable to AbbVie Inc.	4,041	$ 0	0	0	4,041	0	0
Other comprehensive income (loss), net of tax	(154)	0	0	0	0	(154)	0
Dividends declared	(7,892)	0	0	0	(7,892)	0	0
Purchases of treasury stock	(1,969)	$ 0	(1,969)	0	0	0	0
Purchases of treasury stock (in shares)		(12)
Stock-based compensation plans and other	814	$ 0	38	776	0	0	0
Stock-based compensation plans and other (in shares)		8
Change in noncontrolling interest	2	$ 0	0	0	0	0	2
Ending balance at Sep. 30, 2023	12,129	$ 18	(6,525)	20,021	933	(2,353)	35
Ending balance (in shares) at Sep. 30, 2023		1,765
Beginning balance at Jun. 30, 2023	12,898	$ 18	(6,528)	19,839	1,789	(2,252)	32
Beginning balance (in shares) at Jun. 30, 2023		1,765
Increase (Decrease) in Stockholders' Equity
Net earnings attributable to AbbVie Inc.	1,778	$ 0	0	0	1,778	0	0
Other comprehensive income (loss), net of tax	(101)	0	0	0	0	(101)	0
Dividends declared	(2,634)	0	0	0	(2,634)	0	0
Purchases of treasury stock	(4)	$ 0	(4)	0	0	0	0
Purchases of treasury stock (in shares)		0
Stock-based compensation plans and other	189	$ 0	7	182	0	0	0
Stock-based compensation plans and other (in shares)		0
Change in noncontrolling interest	3	$ 0	0	0	0	0	3
Ending balance at Sep. 30, 2023	$ 12,129	$ 18	$ (6,525)	$ 20,021	$ 933	$ (2,353)	$ 35
Ending balance (in shares) at Sep. 30, 2023		1,765

Financial Instruments and Fair Value Measures

9 Months Ended

Sep. 30, 2023

Fair Value Disclosures [Abstract]

Financial Instruments and Fair Value Measures

Financial Instruments and Fair Value MeasuresRisk Management Policy

See Note 11 to the company’s Annual Report on Form 10-K for the year ended December 31, 2022 for a summary of AbbVie’s risk management policy and use of derivative instruments.

Financial Instruments

Various AbbVie foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany transactions denominated in a currency other than the functional currency of the local entity. These contracts, with notional amounts totaling $2.5 billion at September 30, 2023 and $1.7 billion at December 31, 2022, are designated as cash flow hedges and are recorded at fair value. The durations of these forward exchange contracts were generally less than 18 months. Accumulated gains and losses as of September 30, 2023 are reclassified from accumulated other comprehensive income (loss) (AOCI) and included in cost of products sold at the time the products are sold, generally not exceeding six months from the date of settlement.

In 2019, the company entered into treasury rate lock agreements with notional amounts totaling $10.0 billion to hedge exposure to variability in future cash flows resulting from changes in interest rates related to the issuance of long-term debt in connection with the acquisition of Allergan. The treasury rate lock agreements were designated as cash flow hedges and recorded at fair value. The agreements were net settled upon issuance of the senior notes in 2019 and the resulting net gain was included in AOCI. This gain is reclassified to interest expense, net over the term of the related debt.

The company was a party to interest rate swap contracts designated as cash flow hedges that matured in November 2022. The effect of the hedge contracts was to change a floating-rate interest obligation to a fixed rate for that portion of the floating-rate debt. Realized and unrealized gains or losses were included in AOCI and reclassified to interest expense, net over the lives of the floating-rate debt.

In June 2023, the company entered into a cross-currency swap contract with a notional amount totaling €433 million to hedge the company’s exposure to changes in future cash flows of foreign currency denominated debt related to changes in foreign exchange rates. The cross-currency swap contract was designated as a cash flow hedge and effectively converted the interest and principal payments of the related foreign currency denominated debt to U.S. dollars. The unrealized gains and losses on the contract are included in AOCI and are reclassified to net foreign exchange loss over the term of the related debt.

The company also enters into foreign currency forward exchange contracts to manage its exposure to foreign currency denominated trade payables and receivables and intercompany loans. These contracts are not designated as hedges and are recorded at fair value. Resulting gains or losses are reflected in net foreign exchange gain or loss in the condensed consolidated statements of earnings and are generally offset by losses or gains on the foreign currency exposure being managed. These contracts had notional amounts totaling $6.8 billion at September 30, 2023 and $6.5 billion at December 31, 2022.

The company also uses foreign currency forward exchange contracts or foreign currency denominated debt to hedge its net investments in certain foreign subsidiaries and affiliates. The company had an aggregate principal amount of senior Euro notes designated as net investment hedges of €5.4 billion at September 30, 2023 and €5.9 billion at December 31, 2022. In addition, the company had foreign currency forward exchange contracts designated as net investment hedges with notional amounts totaling €4.9 billion, SEK1.4 billion, CAD750 million and CHF50 million at September 30, 2023 and €4.3 billion, SEK2.0 billion, CAD750 million and CHF90 million at December 31, 2022. The company uses the spot method of assessing hedge effectiveness for derivative instruments designated as net investment hedges. Realized and unrealized gains and losses from these hedges are included in AOCI

and the initial fair value of hedge components excluded from the assessment of effectiveness is recognized in interest expense, net over the life of the hedging instrument.

The company is a party to interest rate swap contracts designated as fair value hedges with notional amounts totaling $5.0 billion at September 30, 2023 and $4.5 billion at December 31, 2022. The effect of the hedge contracts is to change a fixed-rate interest obligation to a floating rate for that portion of the debt. AbbVie records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.

No amounts are excluded from the assessment of effectiveness for cash flow hedges or fair value hedges.

The following table summarizes the amounts and location of AbbVie’s derivative instruments on the condensed consolidated balance sheets:


	Fair value – Derivatives in asset position					Fair value – Derivatives in liability position
(in millions)	Balance sheet caption	September 30, 2023		December 31, 2022		Balance sheet caption	September 30, 2023		December 31, 2022
Foreign currency forward exchange contracts
Designated as cash flow hedges	Prepaid expenses and other	$	90	$	49	Accounts payable and accrued liabilities	$	3	$	8
Designated as cash flow hedges	Other assets	—		1		Other long-term liabilities	—		—
Designated as net investment hedges	Prepaid expenses and other	32		6		Accounts payable and accrued liabilities	29		36
Designated as net investment hedges	Other assets	157		74		Other long-term liabilities	9		47
Not designated as hedges	Prepaid expenses and other	30		33		Accounts payable and accrued liabilities	49		41
Cross-currency swap contracts
Designated as cash flow hedges	Prepaid expenses and other	—		—		Accounts payable and accrued liabilities	5		—
Interest rate swap contracts
Designated as fair value hedges	Prepaid expenses and other	—		—		Accounts payable and accrued liabilities	2		17
Designated as fair value hedges	Other assets	—		—		Other long-term liabilities	434		375
Total derivatives		$	309	$	163		$	531	$	524

While certain derivatives are subject to netting arrangements with the company’s counterparties, the company does not offset derivative assets and liabilities within the condensed consolidated balance sheets.

The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive loss:


	Three months ended September 30,				Nine months ended September 30,
(in millions)	2023		2022		2023		2022
Foreign currency forward exchange contracts
Designated as cash flow hedges	$	76	$	124	$	81	$	171
Designated as net investment hedges	241		362		153		748
Cross-currency swap contracts designated as cash flow hedges	(14)		—		(5)		—
Interest rate swap contracts designated as cash flow hedges	—		—		—		6

Assuming market rates remain constant through contract maturities, the company expects to reclassify pre-tax gains of $74 million into cost of products sold for foreign currency cash flow hedges, pre-tax gains of $1 million into net foreign exchange loss for cross-currency swap cash flow hedges and pre-tax gains of $24 million into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months.

Related to AbbVie’s non-derivative, foreign currency denominated debt designated as net investment hedges, the company recognized in other comprehensive loss pre-tax gains of $173 million for the three months and pre-tax gains of $47 million for the nine months ended September 30, 2023 and pre-tax gains of $431 million for the three months and pre-tax gains of $932 million for the nine months ended September 30, 2022.

The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the condensed consolidated statements of earnings, including the net gains (losses) reclassified out of AOCI into net earnings. See Note 10 for the amount of net gains (losses) reclassified out of AOCI.


		Three months ended September 30,				Nine months ended September 30,
(in millions)	Statement of earnings caption	2023		2022		2023		2022
Foreign currency forward exchange contracts
Designated as cash flow hedges	Cost of products sold	$	11	$	21	$	67	$	47
Designated as net investment hedges	Interest expense, net	28		29		85		67
Not designated as hedges	Net foreign exchange loss	(41)		(121)		(7)		(285)
Treasury rate lock agreements designated as cash flow hedges	Interest expense, net	6		6		18		18
Cross-currency swap contracts designated as cash flow hedges	Net foreign exchange loss	(14)		—		(6)		—
Interest rate swap contracts
Designated as cash flow hedges	Interest expense, net	—		—		—		(3)
Designated as fair value hedges	Interest expense, net	(58)		(141)		(44)		(424)
Debt designated as hedged item in fair value hedges	Interest expense, net	58		141		44		424

Fair Value Measures

The fair value hierarchy consists of the following three levels:

•Level 1 – Valuations based on unadjusted quoted prices in active markets for identical assets that the company has the ability to access;

•Level 2 – Valuations based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuations in which all significant inputs are observable in the market; and

•Level 3 – Valuations using significant inputs that are unobservable in the market and include the use of judgment by the company’s management about the assumptions market participants would use in pricing the asset or liability.

The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of September 30, 2023:


			Basis of fair value measurement
(in millions)	Total		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Assets
Cash and equivalents	$	13,287	$	5,531	$	7,756	$	—
Money market funds and time deposits	10		—		10		—
Debt securities	28		—		28		—
Equity securities	109		86		23		—


Foreign currency contracts	309		—		309		—

Total assets	$	13,743	$	5,617	$	8,126	$	—
Liabilities
Interest rate swap contracts	$	436	$	—	$	436	$	—
Cross-currency swap contracts	5		—		5		—
Foreign currency contracts	90		—		90		—
Contingent consideration	18,674		—		—		18,674
Total liabilities	$	19,205	$	—	$	531	$	18,674

The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of December 31, 2022:


			Basis of fair value measurement
(in millions)	Total		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Assets
Cash and equivalents	$	9,201	$	4,201	$	5,000	$	—
Money market funds and time deposits	21		—		21		—
Debt securities	28		—		28		—
Equity securities	91		59		32		—
Foreign currency contracts	163		—		163		—
Total assets	$	9,504	$	4,260	$	5,244	$	—
Liabilities
Interest rate swap contracts	$	392	$	—	$	392	$	—
Foreign currency contracts	132		—		132		—
Contingent consideration	16,384		—		—		16,384
Total liabilities	$	16,908	$	—	$	524	$	16,384

Money market funds and time deposits are valued using relevant observable market inputs including quoted prices for similar assets and interest rate curves. Equity securities primarily consist of investments for which the fair values were determined by using the published market prices per unit multiplied by the number of units held, without consideration of transaction costs. The derivatives entered into by the company were valued using observable market inputs including published interest rate curves and both forward and spot prices for foreign currencies.

The fair value measurements of the contingent consideration liabilities were determined based on significant unobservable inputs, including the discount rate, estimated probabilities and timing of achieving specified development, regulatory and commercial milestones and the estimated amount of future sales of the acquired products. The potential contingent consideration payments are estimated by applying a probability-weighted expected payment model for contingent milestone payments and a Monte Carlo simulation model for contingent royalty payments, which are then discounted to present value. Changes to the fair value of the contingent consideration liabilities can result from changes to one or a number of inputs, including discount rates, the probabilities of achieving the milestones, the time required to achieve the milestones and estimated future sales. Significant judgment is employed in determining the appropriateness of certain of these inputs. Changes to the inputs described above could have a material impact on the company's financial position and results of operations in any given period.

The fair value of the company's contingent consideration liabilities was calculated using the following significant unobservable inputs:


	September 30, 2023		December 31, 2022
(in millions)	Range	Weighted average(a)	Range	Weighted average(a)
Discount rate	5.3% - 6.1%	5.5%	4.7%- 5.1%	4.8%
Probability of payment for unachieved milestones	100% - 100%	100%	100% - 100%	100%
Probability of payment for royalties by indication(b)	89% - 100%	99%	56% - 100%	99%
Projected year of payments	2023 - 2034	2027	2023 - 2034	2028

(a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities.

(b) Excluding approved indications, the estimated probability of payment was 89% at September 30, 2023 and 56% at December 31, 2022.

There have been no transfers of assets or liabilities into or out of Level 3 of the fair value hierarchy. The following table presents the changes in fair value of total contingent consideration liabilities which are measured using Level 3 inputs:


	Nine months ended September 30,
(in millions)	2023		2022
Beginning balance	$	16,384	$	14,887
Change in fair value recognized in net earnings	3,432		647
Payments	(1,142)		(978)
Ending balance	$	18,674	$	14,556

The change in fair value recognized in net earnings is recorded in other expense (income), net in the condensed consolidated statements of earnings. Contingent consideration payments of amounts up to the initial acquisition date fair value are classified as cash outflows from financing activities and payments of amounts in excess of the initial acquisition date fair value are classified as cash outflows from operating activities in the condensed consolidated statements of cash flows.

Certain financial instruments are carried at historical cost or some basis other than fair value. The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of September 30, 2023 are shown in the table below:


					Basis of fair value measurement
(in millions)	Book value		Approximate fair value		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)



Liabilities
Short-term borrowings	$	2	$	2	$	—	$	2	$	—
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	5,113		5,041		4,763		278		—
Long-term debt and finance lease obligations, excluding fair value hedges	56,035		49,633		49,124		509		—
Total liabilities	$	61,150	$	54,676	$	53,887	$	789	$	—

The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2022 are shown in the table below:


					Basis of fair value measurement
(in millions)	Book value		Approximate fair value		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)



Liabilities
Short-term borrowings	$	1	$	1	$	—	$	1	$	—
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	4,152		4,121		3,930		191		—
Long-term debt and finance lease obligations, excluding fair value hedges	59,463		54,073		53,365		708		—
Total liabilities	$	63,616	$	58,195	$	57,295	$	900	$	—

AbbVie also holds investments in equity securities that do not have readily determinable fair values. The company records these investments at cost and remeasures them to fair value based on certain observable price changes or impairment events as they occur. The carrying amount of these investments was $131 million as of September 30, 2023 and $129 million as of December 31, 2022. No significant cumulative upward or downward adjustments have been recorded for these investments as of September 30, 2023.

Concentrations of Risk

Of total net accounts receivable, three U.S. wholesalers accounted for 81% as of September 30, 2023 and 82% as of December 31, 2022, and substantially all of AbbVie’s pharmaceutical product net revenues in the United States were to these three wholesalers.

Humira (adalimumab) is AbbVie’s single largest product and accounted for approximately 28% of AbbVie’s total net revenues for the nine months ended September 30, 2023 and 36% for the nine months ended September 30, 2022.

Debt and Credit Facilities

Long-Term Debt

In January 2023, the company repaid a $1.0 billion floating rate three-year term loan that was scheduled to mature in May 2023. In March 2023, the company repaid a $350 million aggregate principal amount of 2.80% senior notes at maturity.

In May 2023, the company repaid $1.0 billion aggregate principal amount of 2.85% senior notes at maturity.

In January 2022, the company repaid $2.9 billion aggregate principal amount of 3.45% senior notes that were scheduled to mature in March 2022. This repayment was made by exercising, under the terms of the notes, 60-day early redemption at 100% of the principal amount.

In February 2022, the company refinanced its $2.0 billion floating rate five-year term loan. As part of the refinancing, the company repaid the existing $2.0 billion term loan due May 2025 and borrowed $2.0 billion under a new term loan at a lower floating rate. All other significant terms of the loan, including the maturity date, remained unchanged after the refinancing.

In July 2022, the company repaid $1.7 billion aggregate principal amount of 3.25% senior notes that were scheduled to mature in October 2022. This repayment was made by exercising, under the terms of the notes, 90-day early redemption at 100% of the principal amount.

In September 2022, the company repaid $1.0 billion aggregate principal amount of 3.2% senior notes that were scheduled to mature in November 2022. This payment was made by exercising, under the terms of the notes, 60-day early redemption at 100% of the principal amount.

Short-Term Borrowings

In March 2023, AbbVie entered into an amended and restated five-year revolving credit facility. The amendment increased the unsecured revolving credit facility commitments from $4.0 billion to $5.0 billion and extended the maturity date of the facility from August 2023 to March 2028. This amended facility enables the company to borrow funds on an unsecured basis at variable interest rates and contains various covenants. At September 30, 2023, the company was in compliance with all covenants, and commitment fees under the credit facility were insignificant. No amounts were outstanding under the company's credit facilities as of September 30, 2023 and December 31, 2022.

Equity (Tables)

9 Months Ended

Sep. 30, 2023

Stockholders' Equity Note [Abstract]

Summary of share-based compensation expense

Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and the AbbVie Amended and Restated 2013 Incentive Stock Program and is summarized as follows:


	Three months ended September 30,				Nine months ended September 30,
(in millions)	2023		2022		2023		2022
Cost of products sold	$	9	$	8	$	38	$	33
Research and development	53		47		227		194
Selling, general and administrative	68		71		357		312
Pre-tax compensation expense	130		126		622		539
Tax benefit	(26)		(25)		(111)		(102)
After-tax compensation expense	$	104	$	101	$	511	$	437

Summary of quarterly cash dividends

The following table summarizes quarterly cash dividends declared during 2023 and 2022:


2023				2022
Date Declared	Payment Date	Dividend Per Share		Date Declared	Payment Date	Dividend Per Share
10/26/23	02/15/24	$	1.55	10/28/22	02/15/23	$	1.48
09/08/23	11/15/23	$	1.48	09/09/22	11/15/22	$	1.41
06/22/23	08/15/23	$	1.48	06/23/22	08/15/22	$	1.41
02/16/23	05/15/23	$	1.48	02/17/22	05/16/22	$	1.41

Summary of changes in balances of each component of accumulated other comprehensive loss

The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2023:


(in millions)	Foreign currency translation adjustments		Net investment hedging activities		Pension and post-employment benefits		Cash flow hedging activities		Total
Balance as of December 31, 2022	$	(1,513)	$	464	$	(1,458)	$	308	$	(2,199)
Other comprehensive income (loss) before reclassifications	(279)		156		43		61		(19)
Net gains reclassified from accumulated other comprehensive loss	—		(67)		(5)		(63)		(135)
Net current-period other comprehensive income (loss)	(279)		89		38		(2)		(154)
Balance as of September 30, 2023	$	(1,792)	$	553	$	(1,420)	$	306	$	(2,353)

The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2022:


(in millions)	Foreign currency translation adjustments		Net investment hedging activities		Pension and post-employment benefits		Cash flow hedging activities		Total
Balance as of December 31, 2021	$	(570)	$	(91)	$	(2,546)	$	308	$	(2,899)
Other comprehensive income (loss) before reclassifications	(2,043)		1,318		6		151		(568)
Net losses (gains) reclassified from accumulated other comprehensive loss	—		(53)		130		(53)		24
Net current-period other comprehensive income (loss)	(2,043)		1,265		136		98		(544)
Balance as of September 30, 2022	$	(2,613)	$	1,174	$	(2,410)	$	406	$	(3,443)

Schedule of the significant amounts reclassified out of each component of accumulated other comprehensive loss

The following table presents the impact on AbbVie’s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss:


	Three months ended September 30,				Nine months ended September 30,
(in millions) (brackets denote gains)	2023		2022		2023		2022
Net investment hedging activities
Gains on derivative amount excluded from effectiveness testing(a)	$	(28)	$	(29)	$	(85)	$	(67)
Tax expense	6		6		18		14
Total reclassifications, net of tax	$	(22)	$	(23)	$	(67)	$	(53)
Pension and post-employment benefits
Amortization of actuarial losses and other(b)	$	(2)	$	55	$	(5)	$	166
Tax benefit	—		(12)		—		(36)
Total reclassifications, net of tax	$	(2)	$	43	$	(5)	$	130
Cash flow hedging activities
Gains on foreign currency forward exchange contracts(c)	$	(11)	$	(21)	$	(67)	$	(47)
Gains on treasury rate lock agreements(a)	(6)		(6)		(18)		(18)
Losses on cross-currency swap contracts(d)	14		—		6		—
Losses on interest rate swap contracts(a)	—		—		—		3
Tax expense	2		4		16		9
Total reclassifications, net of tax	$	(1)	$	(23)	$	(63)	$	(53)

(a) Amounts are included in interest expense, net (see Note 8).

(b) Amounts are included in the computation of net periodic benefit cost (see Note 9).

(d) Amounts are included in net foreign exchange loss (see Note 8).

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Basic EPS
Net earnings attributable to AbbVie Inc.	$ 1,778	$ 3,949	$ 4,041	$ 9,363
Earnings allocated to participating securities	11	18	32	43
Earnings available to common shareholders	$ 1,767	$ 3,931	$ 4,009	$ 9,320
Weighted-average basic shares outstanding (in shares)	1,767	1,771	1,768	1,771
Basic earnings per share (in dollars per share)	$ 1.00	$ 2.22	$ 2.27	$ 5.26
Diluted EPS
Net earnings attributable to AbbVie Inc.	$ 1,778	$ 3,949	$ 4,041	$ 9,363
Earnings allocated to participating securities	11	18	32	43
Earnings available to common shareholders	$ 1,767	$ 3,931	$ 4,009	$ 9,320
Weighted-average basic shares outstanding (in shares)	1,767	1,771	1,768	1,771
Effect of dilutive securities (in shares)	4	5	4	6
Weighted-average diluted shares outstanding (in shares)	1,771	1,776	1,772	1,777
Diluted earnings per share (in dollars per share)	$ 1.00	$ 2.21	$ 2.26	$ 5.24

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2023	Oct. 27, 2023
Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	001-35565
Entity Registrant Name	AbbVie Inc.
Entity Central Index Key	0001551152
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	32-0375147
Entity Address, Address Line One	1 North Waukegan Road
Entity Address, City or Town	North Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60064-6400
City Area Code	847
Local Phone Number	932-7900
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		1,765,537,421
NEW YORK STOCK EXCHANGE, INC. \| Common stock
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	ABBV
NEW YORK STOCK EXCHANGE, INC. \| Sec 1.500 Senior Notes Due 2023
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	1.500% Senior Notes due 2023
Trading Symbol	ABBV23B
NEW YORK STOCK EXCHANGE, INC. \| Sec 1.375 Senior Notes Due 2024
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	1.375% Senior Notes due 2024
Trading Symbol	ABBV24
NEW YORK STOCK EXCHANGE, INC. \| Sec 1.250 Senior Notes Due 2024
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	1.250% Senior Notes due 2024
Trading Symbol	ABBV24B
NEW YORK STOCK EXCHANGE, INC. \| Sec 0.750 Senior Notes Due 2027
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	0.750% Senior Notes due 2027
Trading Symbol	ABBV27
NEW YORK STOCK EXCHANGE, INC. \| Sec 2.125 Senior Notes due 2028
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	2.125% Senior Notes due 2028
Trading Symbol	ABBV28
NEW YORK STOCK EXCHANGE, INC. \| Sec 2.625 Senior Notes Due 2028
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	2.625% Senior Notes due 2028
Trading Symbol	ABBV28B
NEW YORK STOCK EXCHANGE, INC. \| Sec 2.125 Senior Notes Due 2029
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	2.125% Senior Notes due 2029
Trading Symbol	ABBV29
NEW YORK STOCK EXCHANGE, INC. \| Sec 1.250 Senior Notes due 2031
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	1.250% Senior Notes due 2031
Trading Symbol	ABBV31
CHICAGO STOCK EXCHANGE, INC \| Common stock
Entity Information
Security Exchange Name	CHX
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	ABBV

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2023
Trading Arrangements, by Individual
Non-Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Terminated	false

Goodwill and Intangible Assets - Intangible Assets, Net (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Aug. 29, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets
Gross carrying amount	$ 84,787		$ 84,787			$ 96,172
Accumulated amortization	(26,469)		(26,469)			(29,645)
Net carrying amount	58,318		58,318			66,527
Indefinite-lived intangible assets	285		285			912
Total intangible assets gross carrying amount	85,072		85,072			97,084
Intangible assets, net	58,603		58,603			67,439
Finite-Lived Intangible Assets, Fair Value Disclosure					$ 1,900
Amortization expense	2,000	$ 2,000	6,057	$ 5,728
Vuity
Finite-Lived Intangible Assets
Impairment of Intangible Assets, Finite-Lived		$ 770
Imbruvica
Finite-Lived Intangible Assets
Impairment of Intangible Assets, Finite-Lived	2,100
AGN-151607
Indefinite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible asset impairment charges			630
Developed product rights
Finite-Lived Intangible Assets
Gross carrying amount	76,526		76,526			87,698
Accumulated amortization	(21,170)		(21,170)			(25,003)
Net carrying amount	55,356		55,356			62,695
Developed product rights \| Imbruvica
Finite-Lived Intangible Assets
Net carrying amount	1,800		1,800		$ 4,000
License agreements
Finite-Lived Intangible Assets
Gross carrying amount	8,261		8,261			8,474
Accumulated amortization	(5,299)		(5,299)			(4,642)
Net carrying amount	$ 2,962		$ 2,962			$ 3,832

Post-Employment Benefits

9 Months Ended

Sep. 30, 2023

Postemployment Benefits [Abstract]

Post-Employment Benefits

The following table summarizes net periodic benefit cost relating to the company’s defined benefit and other post-employment plans:


	Defined benefit plans								Other post- employment plans
	Three months ended September 30,				Nine months ended September 30,				Three months ended September 30,				Nine months ended September 30,
(in millions)	2023		2022		2023		2022		2023		2022		2023		2022
Service cost	$	68	$	113	$	203	$	342	$	9	$	13	$	27	$	38
Interest cost	108		74		324		223		9		6		28		18
Expected return on plan assets	(181)		(177)		(543)		(536)		—		—		—		—
Amortization of prior service cost (credit)	—		1		1		2		(9)		(10)		(27)		(29)
Amortization of actuarial loss	4		57		12		173		3		7		9		20
Net periodic benefit cost (credit)	$	(1)	$	68	$	(3)	$	204	$	12	$	16	$	37	$	47

The components of net periodic benefit cost other than service cost are included in other expense (income), net in the condensed consolidated statements of earnings.

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The effective tax rate was 9% for the three months and 20% for the nine months ended September 30, 2023 compared to 10% for the three months and 11% for the nine months ended September 30, 2022. The effective tax rate in each period differed from the U.S. statutory tax rate of 21% principally due to the impact of foreign operations which reflects the impact of lower income tax rates in locations outside the United States and business development activities. The effective tax rate for the nine months ended September 30, 2023 and September 30, 2022 and the three months ended September 30, 2022 were also impacted by changes in fair value of contingent consideration. The increase in the effective tax rate for the nine months ended September 30, 2023 over the prior year was primarily due to changes in fair value of contingent consideration.Due to the potential for resolution of federal, state and foreign examinations and the expiration of various statutes of limitations, it is reasonably possible the company’s gross unrecognized tax benefits balance may change within the next 12 months by up to $620 million.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

+ Details

Segment Information (Tables)

9 Months Ended

Sep. 30, 2023

Segment Reporting [Abstract]

Schedule of worldwide net revenues

The following table details AbbVie’s worldwide net revenues:


		Three months ended September 30,				Nine months ended September 30,

(in millions)		2023		2022		2023		2022
Immunology
Humira	United States	$	3,020	$	4,956	$	9,420	$	13,613
	International	527		603		1,680		2,045
	Total	$	3,547	$	5,559	$	11,100	$	15,658
Skyrizi	United States	$	1,875	$	1,221	$	4,648	$	3,081
	International	251		176		721		508
	Total	$	2,126	$	1,397	$	5,369	$	3,589
Rinvoq	United States	$	801	$	505	$	1,895	$	1,228
	International	309		190		819		524
	Total	$	1,110	$	695	$	2,714	$	1,752
Oncology
Imbruvica	United States	$	678	$	849	$	1,982	$	2,585
	Collaboration revenues	230		286		711		868
	Total	$	908	$	1,135	$	2,693	$	3,453
Venclexta	United States	$	281	$	259	$	811	$	740
	International	309		256		888		753
	Total	$	590	$	515	$	1,699	$	1,493
Epkinly	Collaboration revenues	$	14	$	—	$	14	$	—
Aesthetics
Botox Cosmetic	United States	$	388	$	370	$	1,217	$	1,232
	International	232		267		747		741
	Total	$	620	$	637	$	1,964	$	1,973
Juvederm Collection	United States	$	116	$	125	$	363	$	420
	International	205		227		681		686
	Total	$	321	$	352	$	1,044	$	1,106
Other Aesthetics	United States	$	255	$	265	$	785	$	837
	International	43		47		130		130
	Total	$	298	$	312	$	915	$	967
Neuroscience
Botox Therapeutic	United States	$	626	$	584	$	1,827	$	1,641
	International	122		115		388		350
	Total	$	748	$	699	$	2,215	$	1,991
Vraylar	United States	$	750	$	554	$	1,967	$	1,473
	International	1		—		3		—
	Total	$	751	$	554	$	1,970	$	1,473
Duodopa	United States	$	25	$	22	$	74	$	72
	International	93		88		279		279
	Total	$	118	$	110	$	353	$	351
Ubrelvy	United States	$	230	$	160	$	574	$	483
	International	3		—		7		—
	Total	$	233	$	160	$	581	$	483


		Three months ended September 30,				Nine months ended September 30,

(in millions)		2023		2022		2023		2022
Qulipta	United States	$	131	$	62	$	292	$	106
	International	1		—		2		—
	Total	$	132	$	62	$	294	$	106
Other Neuroscience	United States	$	55	$	82	$	195	$	400
	International	6		5		15		14
	Total	$	61	$	87	$	210	$	414
Eye Care
Ozurdex	United States	$	34	$	35	$	107	$	104
	International	86		71		247		219
	Total	$	120	$	106	$	354	$	323
Lumigan/Ganfort	United States	$	28	$	59	$	142	$	186
	International	63		62		198		205
	Total	$	91	$	121	$	340	$	391
Alphagan/Combigan	United States	$	30	$	37	$	90	$	161
	International	40		36		116		111
	Total	$	70	$	73	$	206	$	272
Restasis	United States	$	104	$	132	$	265	$	518
	International	13		10		43		38
	Total	$	117	$	142	$	308	$	556
Other Eye Care	United States	$	114	$	99	$	334	$	296
	International	93		82		288		273
	Total	$	207	$	181	$	622	$	569
Other Key Products
Mavyret	United States	$	167	$	190	$	531	$	562
	International	203		193		590		599
	Total	$	370	$	383	$	1,121	$	1,161
Creon	United States	$	305	$	336	$	892	$	941
Linzess/Constella	United States	$	279	$	262	$	799	$	742
	International	9		9		26		24
	Total	$	288	$	271	$	825	$	766



All other		$	782	$	925	$	2,214	$	3,145
Total net revenues		$	13,927	$	14,812	$	40,017	$	42,933

Earnings Per Share (Tables)

9 Months Ended

Sep. 30, 2023

Earnings Per Share [Abstract]

Schedule of basic and diluted earnings per share, impact of two-class method

The following table summarizes the impact of the two-class method:


	Three months ended September 30,				Nine months ended September 30,
(in millions, except per share data)	2023		2022		2023		2022
Basic EPS
Net earnings attributable to AbbVie Inc.	$	1,778	$	3,949	$	4,041	$	9,363
Earnings allocated to participating securities	11		18		32		43
Earnings available to common shareholders	$	1,767	$	3,931	$	4,009	$	9,320
Weighted-average basic shares outstanding	1,767		1,771		1,768		1,771
Basic earnings per share attributable to AbbVie Inc.	$	1.00	$	2.22	$	2.27	$	5.26

Diluted EPS
Net earnings attributable to AbbVie Inc.	$	1,778	$	3,949	$	4,041	$	9,363
Earnings allocated to participating securities	11		18		32		43
Earnings available to common shareholders	$	1,767	$	3,931	$	4,009	$	9,320
Weighted-average shares of common stock outstanding	1,767		1,771		1,768		1,771
Effect of dilutive securities	4		5		4		6
Weighted-average diluted shares outstanding	1,771		1,776		1,772		1,777
Diluted earnings per share attributable to AbbVie Inc.	$	1.00	$	2.21	$	2.26	$	5.24

Collaborations (Tables)

9 Months Ended

Sep. 30, 2023

Janssen Biotech Inc.

Collaborative and license agreements

Schedule of profit and cost sharing relationship

The following table shows the profit and cost sharing relationship between Janssen and AbbVie:


	Three months ended September 30,				Nine months ended September 30,
(in millions)	2023		2022		2023		2022
United States - Janssen's share of profits (included in cost of products sold)	$	316	$	398	$	925	$	1,210
International - AbbVie's share of profits (included in net revenues)	230		286		711		868
Global - AbbVie's share of other costs (included in respective line items)	59		63		171		196

Genentech, Inc.

Collaborative and license agreements

Schedule of profit and cost sharing relationship

The following table shows the profit and cost sharing relationship between Genentech and AbbVie:


	Three months ended September 30,				Nine months ended September 30,
(in millions)	2023		2022		2023		2022
Genentech's share of profits, including royalties (included in cost of products sold)	$	225	$	204	$	641	$	578
AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A)	13		10		32		27
AbbVie's share of development costs (included in R&D)	24		29		82		87

Integration and Restructuring Plans

9 Months Ended

Sep. 30, 2023

Restructuring and Related Activities [Abstract]

Integration and Restructuring Plans

Allergan Integration Plan

Following the closing of the Allergan acquisition, AbbVie implemented an integration plan designed to reduce costs, integrate and optimize the combined organization and incurred total cumulative charges of $2.5 billion through September 30, 2023. These costs consist of severance and employee benefit costs (cash severance, non-cash severance including accelerated equity award compensation expense, retention and other termination benefits) and other integration expenses.

The following table summarizes the charges (benefits) associated with the Allergan acquisition integration plan:


	Three months ended September 30,				Nine months ended September 30,
(in millions)	2023		2022		2023		2022
Cost of products sold	$	20	$	24	$	66	$	81
Research and development	1		4		2		14
Selling, general and administrative	39		88		134		234
Total charges	$	60	$	116	$	202	$	329

The following table summarizes the cash activity in the recorded liability associated with the Allergan integration plan for the nine months ended September 30, 2023:


(in millions)
Accrued balance as of December 31, 2022	$	107
Charges	192
Payments and other adjustments	(258)
Accrued balance as of September 30, 2023	$	41

Other Restructuring

AbbVie recorded restructuring charges of $10 million for the three months and $55 million for the nine months ended September 30, 2023 and $50 million for the three months and $143 million for the nine months ended September 30, 2022.

The following table summarizes the cash activity in the restructuring reserve for the nine months ended September 30, 2023:


(in millions)
Accrued balance as of December 31, 2022	$	176
Restructuring charges	31
Payments and other adjustments	(64)
Accrued balance as of September 30, 2023	$	143

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Statement of Cash Flows [Abstract]
Net earnings	$ 4,049	$ 9,373
Adjustments to reconcile net earnings to net cash from operating activities:
Depreciation	565	582
Amortization of intangible assets	6,057	5,728
Deferred income taxes	(1,498)	(1,415)
Change in fair value of contingent consideration liabilities	3,432	647
Payment for Contingent Consideration Liability, Operating Activities	(407)	(161)
Stock-based compensation	622	539
Acquired IPR&D and milestones	496	454
Gain on divestitures		(172)
Non-cash litigation reserve adjustments, net of cash payments	(205)	2,261
Impairment of Intangible Assets (Excluding Goodwill)	2,824	770
Other, net	(219)	(151)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	(273)	(1,039)
Inventories	(513)	(516)
Prepaid expenses and other assets	394	(60)
Accounts payable and other liabilities	3,661	491
Income tax assets and liabilities, net	(899)	184
Cash flows from operating activities	18,086	17,515
Cash flows from investing activities
Acquisitions and investments	(670)	(494)
Acquisitions of property and equipment	(572)	(482)
Purchases of investment securities	(43)	(1,428)
Sales and maturities of investment securities	41	1,460
Other, net	35	769
Cash flows from investing activities	(1,209)	(175)
Cash flows from financing activities
Proceeds from issuance of long-term debt	0	2,000
Repayments of long-term debt and finance lease obligations	(2,355)	(7,582)
Dividends paid	(7,913)	(7,537)
Purchases of treasury stock	(1,969)	(1,483)
Proceeds from the exercise of stock options	149	209
Payments of contingent consideration liabilities	(735)	(817)
Other, net	50	41
Cash flows from financing activities	(12,773)	(15,169)
Effect of exchange rate changes on cash and equivalents	(18)	(85)
Net change in cash and equivalents	4,086	2,086
Cash and equivalents, beginning of period	9,201	9,746
Cash and equivalents, end of period	$ 13,287	$ 11,832

Equity - RSUs and Performance Shares (Details) - RSUs and Performance Shares $ / shares in Units, shares in Millions, $ in Millions	9 Months Ended
	Sep. 30, 2023 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award
Shares granted (in shares) \| shares	5.8
Fair market value of awards vested (in dollars per share) \| $ / shares	$ 149.59
Unrecognized compensation cost \| $	$ 692
Period for recognition of unrecognized compensation cost	2 years

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

Financial Instruments and Fair Value Measures - Significant Level 3 Unobservable Inputs (Details)

Sep. 30, 2023

Dec. 31, 2022

Weighted average | Discount rate

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Significant unobservable input for contingent consideration

^[1]

0.055

0.048

Weighted average | Probability of payment for unachieved milestones

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Significant unobservable input for contingent consideration

^[1]

Weighted average | Probability of payment for royalties by indication

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Significant unobservable input for contingent consideration

^[1],[2]

0.99

Weighted average | Projected year of payments

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Significant unobservable input for contingent consideration

^[1]

2,027

2,028

Minimum | Discount rate

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Significant unobservable input for contingent consideration

0.053

0.047

Minimum | Probability of payment for unachieved milestones

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Significant unobservable input for contingent consideration

Minimum | Probability of payment for royalties by indication

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Significant unobservable input for contingent consideration

^[2]

0.89

0.56

Minimum | Projected year of payments

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Significant unobservable input for contingent consideration

2,023

Minimum | Probability of payment for royalties excluding approved indications

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Significant unobservable input for contingent consideration

0.89

0.56

Maximum | Discount rate

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Significant unobservable input for contingent consideration

0.061

0.051

Maximum | Probability of payment for unachieved milestones

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Significant unobservable input for contingent consideration

Maximum | Probability of payment for royalties by indication

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Significant unobservable input for contingent consideration

^[2]

Maximum | Projected year of payments

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Significant unobservable input for contingent consideration

2,034

Maximum | Probability of payment for royalties excluding approved indications

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Significant unobservable input for contingent consideration

0.89

0.56

[1]	(a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities.
[2]	(b) Excluding approved indications, the estimated probability of payment was 89% at September 30, 2023 and 56% at December 31, 2022.

Financial Instruments and Fair Value Measures - Financial Instruments (Details) SFr in Millions, $ in Millions, € in Billions, kr in Billions	9 Months Ended
	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 EUR (€)	Sep. 30, 2023 SEK (kr)	Sep. 30, 2023 CAD ($)	Sep. 30, 2023 CHF (SFr)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 EUR (€)	Dec. 31, 2022 SEK (kr)	Dec. 31, 2022 CAD ($)	Dec. 31, 2022 CHF (SFr)	Dec. 31, 2019 USD ($)
Derivative instruments, notional amount and fair value
Amount excluded from the assessment of effectiveness for cash flow hedges	$ 0	$ 0
Amount excluded from the assessment of effectiveness for fair value hedges	0	$ 0
Fair value - Derivatives in asset position	309,000,000						$ 163,000,000
Fair value - Derivatives in liability position	531,000,000						524,000,000
Designated as hedging instrument \| Net investment hedges \| Senior notes
Derivative instruments, notional amount and fair value
Principal amount of unsecured senior notes \| €			€ 5.4					€ 5.9
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Cash flow hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments	$ 2,500,000,000						1,700,000,000
Duration of forward exchange contracts	18 months
Approximate length of time over which accumulated gains and losses will be recognized in Cost of products sold	6 months
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Cash flow hedges \| Prepaid expenses and other
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position	$ 90,000,000						49,000,000
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Cash flow hedges \| Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position	3,000,000						8,000,000
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Cash flow hedges \| Other assets
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position	0						1,000,000
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Cash flow hedges \| Other long-term liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position	0						0
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Net investment hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments			€ 4.9	kr 1.4	$ 750	SFr 50		€ 4.3	kr 2.0	$ 750	SFr 90
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Net investment hedges \| Prepaid expenses and other
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position	32,000,000						6,000,000
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Net investment hedges \| Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position	29,000,000						36,000,000
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Net investment hedges \| Other assets
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position	157,000,000						74,000,000
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Net investment hedges \| Other long-term liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position	9,000,000						47,000,000
Designated as hedging instrument \| Treasury rate lock agreements \| Cash flow hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments												$ 10,000,000,000
Designated as hedging instrument \| Cross-currency swap contracts \| Cash flow hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments	433,000,000
Designated as hedging instrument \| Cross-currency swap contracts \| Cash flow hedges \| Prepaid expenses and other
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position	0						0
Designated as hedging instrument \| Cross-currency swap contracts \| Cash flow hedges \| Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position	5,000,000						0
Designated as hedging instrument \| Interest rate swap contracts \| Fair value hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments	5,000,000,000						4,500,000,000
Designated as hedging instrument \| Interest rate swap contracts \| Fair value hedges \| Prepaid expenses and other
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position	0						0
Designated as hedging instrument \| Interest rate swap contracts \| Fair value hedges \| Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position	2,000,000						17,000,000
Designated as hedging instrument \| Interest rate swap contracts \| Fair value hedges \| Other assets
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position	0						0
Designated as hedging instrument \| Interest rate swap contracts \| Fair value hedges \| Other long-term liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position	434,000,000						375,000,000
Not designated as hedging instrument \| Foreign currency forward exchange contracts
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments	6,800,000,000						6,500,000,000
Not designated as hedging instrument \| Foreign currency forward exchange contracts \| Prepaid expenses and other
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position	30,000,000						33,000,000
Not designated as hedging instrument \| Foreign currency forward exchange contracts \| Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position	$ 49,000,000						$ 41,000,000

Post-Employment Benefits (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Post-Employment Benefits (Details) - USD ($) $ in Millions	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Defined benefit plans
Defined benefit and other post-employment plans
Service cost	$ 68	$ 113	$ 203	$ 342
Interest cost	108	74	324	223
Expected return on plan assets	(181)	(177)	(543)	(536)
Amortization of prior service cost (credit)	0	1	1	2
Amortization of actuarial loss	4	57	12	173
Net periodic benefit cost (credit)	(1)	68	(3)	204
Other post-employment plans
Defined benefit and other post-employment plans
Service cost	9	13	27	38
Interest cost	9	6	28	18
Expected return on plan assets	0	0	0	0
Amortization of prior service cost (credit)	(9)	(10)	(27)	(29)
Amortization of actuarial loss	3	7	9	20
Net periodic benefit cost (credit)	$ 12	$ 16	$ 37	$ 47

Equity - Stock-Based Compensation (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award
Pre-tax compensation expense	$ 130	$ 126	$ 622	$ 539
Tax benefit	(26)	(25)	(111)	(102)
After-tax compensation expense	104	101	511	437
Cost of products sold
Share-based Compensation Arrangement by Share-based Payment Award
Pre-tax compensation expense	9	8	38	33
Research and development
Share-based Compensation Arrangement by Share-based Payment Award
Pre-tax compensation expense	53	47	227	194
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award
Pre-tax compensation expense	$ 68	$ 71	$ 357	$ 312

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Condensed Consolidated Statements of Earnings (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Net revenues	$ 13,927	$ 14,812	$ 40,017	$ 42,933
Cost of products sold	6,485	5,022	14,711	13,244
Selling, general and administrative	3,372	3,304	9,679	11,843
Research and development	1,723	1,614	5,748	4,720
Acquired IPR&D and milestones	66	40	496	454
Other operating expense (income), net	0	229	(179)	57
Total operating costs and expenses	11,646	10,209	30,455	30,318
Operating earnings	2,281	4,603	9,562	12,615
Interest expense, net	398	497	1,306	1,568
Net foreign exchange loss	25	36	97	108
Other expense (income), net	(95)	(330)	3,121	427
Earnings before income tax expense	1,953	4,400	5,038	10,512
Income tax expense	172	448	989	1,139
Net earnings	1,781	3,952	4,049	9,373
Net earnings attributable to noncontrolling interest	3	3	8	10
Net earnings attributable to AbbVie Inc.	$ 1,778	$ 3,949	$ 4,041	$ 9,363
Per share data
Basic earnings per share (in dollars per share)	$ 1.00	$ 2.22	$ 2.27	$ 5.26
Diluted earnings per share (in dollars per share)	$ 1.00	$ 2.21	$ 2.26	$ 5.24
Weighted-average basic shares outstanding (in shares)	1,767	1,771	1,768	1,771
Weighted-average diluted shares outstanding (in shares)	1,771	1,776	1,772	1,777

Financial Instruments and Fair Value Measures - Fair Value Measures (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Assets
Foreign currency contracts	$ 309	$ 163
Liabilities
Foreign currency contracts	531	524
Quoted prices in active markets for identical assets (Level 1)
Liabilities
Total liabilities	53,887	57,295
Fair Value, Recurring
Assets
Cash and equivalents	13,287	9,201
Debt securities	28	28
Equity securities	109	91
Total assets	13,743	9,504
Liabilities
Interest rate swap contracts	436	392
Contingent consideration	18,674	16,384
Total liabilities	19,205	16,908
Fair Value, Recurring \| Foreign currency contracts
Assets
Foreign currency contracts	309	163
Liabilities
Foreign currency contracts	90	132
Fair Value, Recurring \| Quoted prices in active markets for identical assets (Level 1)
Assets
Cash and equivalents	5,531	4,201
Debt securities	0	0
Equity securities	86	59
Total assets	5,617	4,260
Liabilities
Interest rate swap contracts	0	0
Contingent consideration	0	0
Total liabilities	0	0
Fair Value, Recurring \| Quoted prices in active markets for identical assets (Level 1) \| Foreign currency contracts
Assets
Foreign currency contracts	0	0
Liabilities
Foreign currency contracts	0	0
Fair Value, Recurring \| Significant other observable inputs (Level 2)
Assets
Cash and equivalents	7,756	5,000
Debt securities	28	28
Equity securities	23	32
Total assets	8,126	5,244
Liabilities
Interest rate swap contracts	436	392
Contingent consideration	0	0
Total liabilities	531	524
Fair Value, Recurring \| Significant other observable inputs (Level 2) \| Foreign currency contracts
Assets
Foreign currency contracts	309	163
Liabilities
Foreign currency contracts	90	132
Fair Value, Recurring \| Significant unobservable inputs (Level 3)
Assets
Cash and equivalents	0	0
Debt securities	0	0
Equity securities	0	0
Total assets	0	0
Liabilities
Interest rate swap contracts	0	0
Contingent consideration	18,674	16,384
Total liabilities	18,674	16,384
Fair Value, Recurring \| Significant unobservable inputs (Level 3) \| Foreign currency contracts
Assets
Foreign currency contracts	0	0
Liabilities
Foreign currency contracts	0	0
Money market funds and time deposits \| Fair Value, Recurring
Assets
Money market funds and time deposits	10	21
Money market funds and time deposits \| Fair Value, Recurring \| Quoted prices in active markets for identical assets (Level 1)
Assets
Money market funds and time deposits	0	0
Money market funds and time deposits \| Fair Value, Recurring \| Significant other observable inputs (Level 2)
Assets
Money market funds and time deposits	10	21
Money market funds and time deposits \| Fair Value, Recurring \| Significant unobservable inputs (Level 3)
Assets
Money market funds and time deposits	$ 0	$ 0

Segment Information

9 Months Ended

Sep. 30, 2023

Segment Reporting [Abstract]

Segment Information

Segment InformationAbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as chief operating decision maker (CODM), to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. Consistent with this structure, a global research and development and supply chain organization is responsible for the discovery, manufacturing and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region or therapeutic area. All of these activities are supported by a global corporate administrative staff. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods.The following table details AbbVie’s worldwide net revenues:


		Three months ended September 30,				Nine months ended September 30,

(in millions)		2023		2022		2023		2022
Immunology
Humira	United States	$	3,020	$	4,956	$	9,420	$	13,613
	International	527		603		1,680		2,045
	Total	$	3,547	$	5,559	$	11,100	$	15,658
Skyrizi	United States	$	1,875	$	1,221	$	4,648	$	3,081
	International	251		176		721		508
	Total	$	2,126	$	1,397	$	5,369	$	3,589
Rinvoq	United States	$	801	$	505	$	1,895	$	1,228
	International	309		190		819		524
	Total	$	1,110	$	695	$	2,714	$	1,752
Oncology
Imbruvica	United States	$	678	$	849	$	1,982	$	2,585
	Collaboration revenues	230		286		711		868
	Total	$	908	$	1,135	$	2,693	$	3,453
Venclexta	United States	$	281	$	259	$	811	$	740
	International	309		256		888		753
	Total	$	590	$	515	$	1,699	$	1,493
Epkinly	Collaboration revenues	$	14	$	—	$	14	$	—
Aesthetics
Botox Cosmetic	United States	$	388	$	370	$	1,217	$	1,232
	International	232		267		747		741
	Total	$	620	$	637	$	1,964	$	1,973
Juvederm Collection	United States	$	116	$	125	$	363	$	420
	International	205		227		681		686
	Total	$	321	$	352	$	1,044	$	1,106
Other Aesthetics	United States	$	255	$	265	$	785	$	837
	International	43		47		130		130
	Total	$	298	$	312	$	915	$	967
Neuroscience
Botox Therapeutic	United States	$	626	$	584	$	1,827	$	1,641
	International	122		115		388		350
	Total	$	748	$	699	$	2,215	$	1,991
Vraylar	United States	$	750	$	554	$	1,967	$	1,473
	International	1		—		3		—
	Total	$	751	$	554	$	1,970	$	1,473
Duodopa	United States	$	25	$	22	$	74	$	72
	International	93		88		279		279
	Total	$	118	$	110	$	353	$	351
Ubrelvy	United States	$	230	$	160	$	574	$	483
	International	3		—		7		—
	Total	$	233	$	160	$	581	$	483


		Three months ended September 30,				Nine months ended September 30,

(in millions)		2023		2022		2023		2022
Qulipta	United States	$	131	$	62	$	292	$	106
	International	1		—		2		—
	Total	$	132	$	62	$	294	$	106
Other Neuroscience	United States	$	55	$	82	$	195	$	400
	International	6		5		15		14
	Total	$	61	$	87	$	210	$	414
Eye Care
Ozurdex	United States	$	34	$	35	$	107	$	104
	International	86		71		247		219
	Total	$	120	$	106	$	354	$	323
Lumigan/Ganfort	United States	$	28	$	59	$	142	$	186
	International	63		62		198		205
	Total	$	91	$	121	$	340	$	391
Alphagan/Combigan	United States	$	30	$	37	$	90	$	161
	International	40		36		116		111
	Total	$	70	$	73	$	206	$	272
Restasis	United States	$	104	$	132	$	265	$	518
	International	13		10		43		38
	Total	$	117	$	142	$	308	$	556
Other Eye Care	United States	$	114	$	99	$	334	$	296
	International	93		82		288		273
	Total	$	207	$	181	$	622	$	569
Other Key Products
Mavyret	United States	$	167	$	190	$	531	$	562
	International	203		193		590		599
	Total	$	370	$	383	$	1,121	$	1,161
Creon	United States	$	305	$	336	$	892	$	941
Linzess/Constella	United States	$	279	$	262	$	799	$	742
	International	9		9		26		24
	Total	$	288	$	271	$	825	$	766



All other		$	782	$	925	$	2,214	$	3,145
Total net revenues		$	13,927	$	14,812	$	40,017	$	42,933

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//280/tableOfContent

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-26

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-34

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-21

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-21

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

+ Details

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Current assets
Cash and equivalents	$ 13,287	$ 9,201
Short-term investments	3	28
Accounts receivable, net	11,412	11,254
Inventories	3,981	3,579
Prepaid expenses and other	4,541	4,401
Total current assets	33,224	28,463
Investments	275	241
Property and equipment, net	4,934	4,935
Intangible assets, net	58,603	67,439
Goodwill	32,091	32,156
Other assets	7,094	5,571
Total assets	136,221	138,805
Current liabilities
Short-term borrowings	2	1
Current portion of long-term debt and finance lease obligations	5,113	4,135
Accounts payable and accrued liabilities	29,658	25,402
Total current liabilities	34,773	29,538
Long-term debt and finance lease obligations	55,631	59,135
Deferred income taxes	2,044	2,190
Other long-term liabilities	31,644	30,655
Commitments and contingencies
Stockholders' equity
Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,822,577,212 shares issued as of September 30, 2023 and 1,813,770,294 as of December 31, 2022	18	18
Common stock held in treasury, at cost, 57,091,177 shares as of September 30, 2023 and 44,589,000 as of December 31, 2022	(6,525)	(4,594)
Additional paid-in capital	20,021	19,245
Retained earnings	933	4,784
Accumulated other comprehensive loss	(2,353)	(2,199)
Total stockholders' equity	12,094	17,254
Noncontrolling interest	35	33
Total equity	12,129	17,287
Total liabilities and equity	$ 136,221	$ 138,805

Legal Proceedings and Contingencies	9 Months Ended
Legal Proceedings and Contingencies	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings and Contingencies	Legal Proceedings and Contingencies AbbVie is subject to contingencies, such as various claims, legal proceedings and investigations regarding product liability, intellectual property, commercial, securities and other matters that arise in the normal course of business. The most significant matters are described below. Loss contingency provisions are recorded for probable losses at management’s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount within a probable range is recorded. For litigation matters discussed below for which a loss is probable or reasonably possible, the company is unable to estimate the possible loss or range of loss, if any, beyond the amounts accrued. Initiation of new legal proceedings or a change in the status of existing proceedings may result in a change in the estimated loss accrued by AbbVie. While it is not feasible to predict the outcome of all proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on AbbVie’s consolidated financial position, results of operations or cash flows. Subject to certain exceptions specified in the separation agreement by and between Abbott Laboratories (Abbott) and AbbVie, AbbVie assumed the liability for, and control of, all pending and threatened legal matters related to its business, including liabilities for any claims or legal proceedings related to products that had been part of its business, but were discontinued prior to the distribution, as well as assumed or retained liabilities, and will indemnify Abbott for any liability arising out of or resulting from such assumed legal matters. Antitrust Litigation Lawsuits are pending against AbbVie and others generally alleging that the 2005 patent litigation settlement involving Niaspan entered into between Kos Pharmaceuticals, Inc. (a company acquired by Abbott in 2006 and presently a subsidiary of AbbVie) and a generic company violated federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys' fees. The lawsuits pending in federal court consist of six individual plaintiff lawsuits and a certified class action by Niaspan direct purchasers. The cases are pending in the United States District Court for the Eastern District of Pennsylvania for coordinated or consolidated pre-trial proceedings under the MDL Rules as In re: Niaspan Antitrust Litigation, MDL No. 2460. In October 2016, the Orange County, California District Attorney’s Office filed a lawsuit on behalf of the State of California regarding the Niaspan patent litigation settlement in Orange County Superior Court, asserting a claim under the unfair competition provision of the California Business and Professions Code seeking injunctive relief, restitution, civil penalties and attorneys’ fees. In August 2019, direct purchasers of AndroGel filed a lawsuit, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al., against AbbVie and others in the United States District Court for the Eastern District of Pennsylvania, alleging that 2006 patent litigation settlements and related agreements by Solvay Pharmaceuticals, Inc. (a company Abbott acquired in February 2010 and now known as AbbVie Products LLC) with three generic companies violated federal antitrust law, and also alleging that 2011 patent litigation by Abbott with two generic companies regarding AndroGel was sham litigation and the settlements of those litigations violated federal antitrust law. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys’ fees. In November 2022, the State of Oregon filed a lawsuit in the Multnomah County, Oregon Circuit Court making similar allegations regarding the 2011 patent litigation with one of the generic companies. Lawsuits were filed against Forest Laboratories, LLC and others generally alleging that 2012 and 2013 patent litigation settlements involving Bystolic with six generic manufacturers violated federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys’ fees. The lawsuits, purported class actions filed on behalf of direct and indirect purchasers of Bystolic, were consolidated as In re: Bystolic Antitrust Litigation in the United States District Court for the Southern District of New York. In February 2023, the court granted Forest Laboratories’ motion to dismiss the cases, dismissing them with prejudice. Plaintiffs are appealing the court’s motion to dismiss ruling. Government Proceedings Lawsuits are pending against Allergan and several other manufacturers generally alleging that they improperly promoted and sold prescription opioid products. Approximately 610 lawsuits are pending against Allergan in federal and state courts. Most of the federal court lawsuits are consolidated for pre-trial purposes in the United States District Court for the Northern District of Ohio under the MDL rules as In re: National Prescription Opiate Litigation, MDL No. 2804. Approximately 160 of the lawsuits are pending in various state courts. The plaintiffs in these lawsuits, which include states, counties, cities, other municipal entities, Native American tribes, union trust funds and other third-party payors, private hospitals and personal injury claimants, generally seek compensatory and punitive damages. Of these approximately 610 lawsuits, approximately 195 of them are brought by states, counties, cities, and other municipal entities. Three other lawsuits are brought by 3 Native American Tribes. AbbVie recorded a charge of $2.1 billion to selling, general and administrative expense in the consolidated statement of earnings in the second quarter of 2022 related to its settlement of over 2,500 lawsuits by states, counties, cities, other municipal entities, and Native American tribes. Approximately 160 of the remaining 198 such lawsuits are in the process of being dismissed with prejudice pursuant to that settlement. In March 2023, AbbVie Inc. filed a petition in the United States Tax Court, AbbVie Inc. and Subsidiaries v. Commissioner of Internal Revenue. The petition disputes the Internal Revenue Service determination concerning a $572 million income tax benefit recorded in 2014 related to a payment made to a third party for the termination of a proposed business combination. Shareholder and Securities Litigation In October 2018, a federal securities lawsuit, Holwill v. AbbVie Inc., et al., was filed in the United States District Court for the Northern District of Illinois against AbbVie, its chief executive officer and former chief financial officer, alleging that reasons stated for Humira sales growth in financial filings between 2013 and 2018 were misleading because they omitted alleged misconduct in connection with Humira patient and reimbursement support services and other services and items of value that allegedly induced Humira prescriptions. In September 2021, the court granted plaintiffs' motion to certify a class. Lawsuits were filed against Allergan and certain of its former officers alleging they made misrepresentations and omissions regarding Allergan's textured breast implants. The lawsuits, which were filed by Allergan shareholders, have been consolidated in the United States District Court for the Southern District of New York as In re: Allergan plc Securities Litigation. The plaintiffs generally seek compensatory damages and attorneys’ fees. In September 2019, the court partially granted Allergan's motion to dismiss. In September 2021, the court granted plaintiffs' motion to certify a class. In December 2022, the court granted Allergan's motion for summary judgment on the remaining claims, dismissing them with prejudice. Plaintiffs are appealing the court's motion to dismiss and summary judgment rulings. In May and July 2022, two shareholder derivative lawsuits, Treppel Family Trust v. Gonzalez et al., and Katcher v. Gonzalez, et al., were filed in the United States District Court for the Northern District of Illinois, alleging that certain AbbVie directors and officers breached fiduciary and other legal duties in making or allowing alleged misstatements regarding the potential effect that safety information about another company’s product would have on the Food and Drug Administration’s approval and labeling for AbbVie’s Rinvoq. Product Liability and General Litigation In April 2023, a putative class action lawsuit, Camargo v. AbbVie Inc., was filed in the United States District Court for the Northern District of Illinois on behalf of Humira patients who paid for Humira based on its list price or who, after losing insurance coverage, discontinued Humira because they could not pay based on its list price, alleging that Humira’s list price is excessive in violation of multiple states’ unfair and deceptive trade practices statutes. The plaintiff generally seeks monetary damages, injunctive relief, and attorneys’ fees. In 2018, a qui tam lawsuit, U.S. ex rel. Silbersher v. Allergan Inc., et al., was filed in the United States District Court for the Northern District of California against several Allergan entities and others, alleging that their conduct before the U.S. Patent Office resulted in false claims for payment being made to federal and state healthcare payors for Namenda XR and Namzaric. The plaintiff-relator sought damages and attorneys' fees under the federal False Claims Act and state law analogues. The federal government and state governments declined to intervene in the lawsuit. In March 2023, the court granted Allergan’s motion to dismiss, dismissing plaintiff-relator’s federal law claims with prejudice and state law claims without prejudice. The plaintiff-relator is appealing the court’s motion to dismiss ruling. Intellectual Property Litigation AbbVie Inc. is seeking to enforce patent rights relating to venetoclax (a drug sold under the trademark Venclexta). Litigation was filed in the United States District Court for the District of Delaware in July 2020 against Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc.; and Alembic Pharmaceuticals Ltd., Alembic Pharmaceuticals, Inc., and Alembic Global Holdings SA. AbbVie alleges defendants’ proposed generic venetoclax products infringe certain patents and seeks declaratory and injunctive relief. Genentech, Inc., which is in a global collaboration with AbbVie concerning the development and marketing of Venclexta, is the co-plaintiff in this suit.

Equity - Stock Options (Details) - Stock Options $ / shares in Units, shares in Millions, $ in Millions	9 Months Ended
	Sep. 30, 2023 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award
Stock options granted (in shares) \| shares	0.6
Weighted-average grant-date fair value of the stock options granted (in dollars per share) \| $ / shares	$ 29.89
Unrecognized compensation cost \| $	$ 7
Period for recognition of unrecognized compensation cost	2 years

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Millions	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Pay vs Performance Disclosure
Net earnings attributable to AbbVie Inc.	$ 1,778	$ 3,949	$ 4,041	$ 9,363

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

Financial Instruments and Fair Value Measures (Tables)

9 Months Ended

Sep. 30, 2023

Fair Value Disclosures [Abstract]

Summary of amounts and location of derivatives on the condensed consolidated balance sheets

The following table summarizes the amounts and location of AbbVie’s derivative instruments on the condensed consolidated balance sheets:


	Fair value – Derivatives in asset position					Fair value – Derivatives in liability position
(in millions)	Balance sheet caption	September 30, 2023		December 31, 2022		Balance sheet caption	September 30, 2023		December 31, 2022
Foreign currency forward exchange contracts
Designated as cash flow hedges	Prepaid expenses and other	$	90	$	49	Accounts payable and accrued liabilities	$	3	$	8
Designated as cash flow hedges	Other assets	—		1		Other long-term liabilities	—		—
Designated as net investment hedges	Prepaid expenses and other	32		6		Accounts payable and accrued liabilities	29		36
Designated as net investment hedges	Other assets	157		74		Other long-term liabilities	9		47
Not designated as hedges	Prepaid expenses and other	30		33		Accounts payable and accrued liabilities	49		41
Cross-currency swap contracts
Designated as cash flow hedges	Prepaid expenses and other	—		—		Accounts payable and accrued liabilities	5		—
Interest rate swap contracts
Designated as fair value hedges	Prepaid expenses and other	—		—		Accounts payable and accrued liabilities	2		17
Designated as fair value hedges	Other assets	—		—		Other long-term liabilities	434		375
Total derivatives		$	309	$	163		$	531	$	524

Schedule of pre-tax amounts of derivatives designated as cash flow hedges recognized in other comprehensive income (loss)

The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive loss:


	Three months ended September 30,				Nine months ended September 30,
(in millions)	2023		2022		2023		2022
Foreign currency forward exchange contracts
Designated as cash flow hedges	$	76	$	124	$	81	$	171
Designated as net investment hedges	241		362		153		748
Cross-currency swap contracts designated as cash flow hedges	(14)		—		(5)		—
Interest rate swap contracts designated as cash flow hedges	—		—		—		6

Schedule of pre-tax amounts of derivatives designated as net investment hedges recognized in other comprehensive income (loss)

The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive loss:


	Three months ended September 30,				Nine months ended September 30,
(in millions)	2023		2022		2023		2022
Foreign currency forward exchange contracts
Designated as cash flow hedges	$	76	$	124	$	81	$	171
Designated as net investment hedges	241		362		153		748
Cross-currency swap contracts designated as cash flow hedges	(14)		—		(5)		—
Interest rate swap contracts designated as cash flow hedges	—		—		—		6

Summary of pre-tax amounts and location of derivatives recognized in the condensed consolidated statements of earnings


		Three months ended September 30,				Nine months ended September 30,
(in millions)	Statement of earnings caption	2023		2022		2023		2022
Foreign currency forward exchange contracts
Designated as cash flow hedges	Cost of products sold	$	11	$	21	$	67	$	47
Designated as net investment hedges	Interest expense, net	28		29		85		67
Not designated as hedges	Net foreign exchange loss	(41)		(121)		(7)		(285)
Treasury rate lock agreements designated as cash flow hedges	Interest expense, net	6		6		18		18
Cross-currency swap contracts designated as cash flow hedges	Net foreign exchange loss	(14)		—		(6)		—
Interest rate swap contracts
Designated as cash flow hedges	Interest expense, net	—		—		—		(3)
Designated as fair value hedges	Interest expense, net	(58)		(141)		(44)		(424)
Debt designated as hedged item in fair value hedges	Interest expense, net	58		141		44		424

Summary of bases used to measure assets and liabilities carried at fair value on a recurring basis


			Basis of fair value measurement
(in millions)	Total		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Assets
Cash and equivalents	$	13,287	$	5,531	$	7,756	$	—
Money market funds and time deposits	10		—		10		—
Debt securities	28		—		28		—
Equity securities	109		86		23		—


Foreign currency contracts	309		—		309		—

Total assets	$	13,743	$	5,617	$	8,126	$	—
Liabilities
Interest rate swap contracts	$	436	$	—	$	436	$	—
Cross-currency swap contracts	5		—		5		—
Foreign currency contracts	90		—		90		—
Contingent consideration	18,674		—		—		18,674
Total liabilities	$	19,205	$	—	$	531	$	18,674

The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of December 31, 2022:


			Basis of fair value measurement
(in millions)	Total		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Assets
Cash and equivalents	$	9,201	$	4,201	$	5,000	$	—
Money market funds and time deposits	21		—		21		—
Debt securities	28		—		28		—
Equity securities	91		59		32		—
Foreign currency contracts	163		—		163		—
Total assets	$	9,504	$	4,260	$	5,244	$	—
Liabilities
Interest rate swap contracts	$	392	$	—	$	392	$	—
Foreign currency contracts	132		—		132		—
Contingent consideration	16,384		—		—		16,384
Total liabilities	$	16,908	$	—	$	524	$	16,384

Summary of significant level 3 unobservable inputs

The fair value of the company's contingent consideration liabilities was calculated using the following significant unobservable inputs:


	September 30, 2023		December 31, 2022
(in millions)	Range	Weighted average(a)	Range	Weighted average(a)
Discount rate	5.3% - 6.1%	5.5%	4.7%- 5.1%	4.8%
Probability of payment for unachieved milestones	100% - 100%	100%	100% - 100%	100%
Probability of payment for royalties by indication(b)	89% - 100%	99%	56% - 100%	99%
Projected year of payments	2023 - 2034	2027	2023 - 2034	2028

(a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities.

(b) Excluding approved indications, the estimated probability of payment was 89% at September 30, 2023 and 56% at December 31, 2022.

Schedule of changes in fair value of Level 3 inputs

The following table presents the changes in fair value of total contingent consideration liabilities which are measured using Level 3 inputs:


	Nine months ended September 30,
(in millions)	2023		2022
Beginning balance	$	16,384	$	14,887
Change in fair value recognized in net earnings	3,432		647
Payments	(1,142)		(978)
Ending balance	$	18,674	$	14,556

Schedule of book values, approximate fair values and bases used to measure certain financial instruments

The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of September 30, 2023 are shown in the table below:


					Basis of fair value measurement
(in millions)	Book value		Approximate fair value		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)



Liabilities
Short-term borrowings	$	2	$	2	$	—	$	2	$	—
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	5,113		5,041		4,763		278		—
Long-term debt and finance lease obligations, excluding fair value hedges	56,035		49,633		49,124		509		—
Total liabilities	$	61,150	$	54,676	$	53,887	$	789	$	—

The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2022 are shown in the table below:


					Basis of fair value measurement
(in millions)	Book value		Approximate fair value		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)



Liabilities
Short-term borrowings	$	1	$	1	$	—	$	1	$	—
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	4,152		4,121		3,930		191		—
Long-term debt and finance lease obligations, excluding fair value hedges	59,463		54,073		53,365		708		—
Total liabilities	$	63,616	$	58,195	$	57,295	$	900	$	—

Segment Information - Disaggregation of Revenue (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue
Total net revenues	$ 13,927	$ 14,812	$ 40,017	$ 42,933
All other
Disaggregation of Revenue
Net revenues	782	925	2,214	3,145
Immunology \| Humira
Disaggregation of Revenue
Net revenues	3,547	5,559	11,100	15,658
Immunology \| Humira \| United States
Disaggregation of Revenue
Net revenues	3,020	4,956	9,420	13,613
Immunology \| Humira \| International
Disaggregation of Revenue
Net revenues	527	603	1,680	2,045
Immunology \| Skyrizi
Disaggregation of Revenue
Net revenues	2,126	1,397	5,369	3,589
Immunology \| Skyrizi \| United States
Disaggregation of Revenue
Net revenues	1,875	1,221	4,648	3,081
Immunology \| Skyrizi \| International
Disaggregation of Revenue
Net revenues	251	176	721	508
Immunology \| Rinvoq
Disaggregation of Revenue
Net revenues	1,110	695	2,714	1,752
Immunology \| Rinvoq \| United States
Disaggregation of Revenue
Net revenues	801	505	1,895	1,228
Immunology \| Rinvoq \| International
Disaggregation of Revenue
Net revenues	309	190	819	524
Hematologic Oncology \| Imbruvica
Disaggregation of Revenue
Net revenues	908	1,135	2,693	3,453
Hematologic Oncology \| Imbruvica \| United States
Disaggregation of Revenue
Net revenues	678	849	1,982	2,585
Hematologic Oncology \| Imbruvica \| International
Disaggregation of Revenue
Collaboration revenues	230	286	711	868
Hematologic Oncology \| Venclexta
Disaggregation of Revenue
Net revenues	590	515	1,699	1,493
Hematologic Oncology \| Venclexta \| United States
Disaggregation of Revenue
Net revenues	281	259	811	740
Hematologic Oncology \| Venclexta \| International
Disaggregation of Revenue
Net revenues	309	256	888	753
Hematologic Oncology \| Epkinly
Disaggregation of Revenue
Collaboration revenues	14	0	14	0
Aesthetics \| Botox Cosmetic
Disaggregation of Revenue
Net revenues	620	637	1,964	1,973
Aesthetics \| Botox Cosmetic \| United States
Disaggregation of Revenue
Net revenues	388	370	1,217	1,232
Aesthetics \| Botox Cosmetic \| International
Disaggregation of Revenue
Net revenues	232	267	747	741
Aesthetics \| Juvederm Collection
Disaggregation of Revenue
Net revenues	321	352	1,044	1,106
Aesthetics \| Juvederm Collection \| United States
Disaggregation of Revenue
Net revenues	116	125	363	420
Aesthetics \| Juvederm Collection \| International
Disaggregation of Revenue
Net revenues	205	227	681	686
Aesthetics \| Other Aesthetics
Disaggregation of Revenue
Net revenues	298	312	915	967
Aesthetics \| Other Aesthetics \| United States
Disaggregation of Revenue
Net revenues	255	265	785	837
Aesthetics \| Other Aesthetics \| International
Disaggregation of Revenue
Net revenues	43	47	130	130
Neuroscience \| Botox Therapeutic
Disaggregation of Revenue
Net revenues	748	699	2,215	1,991
Neuroscience \| Botox Therapeutic \| United States
Disaggregation of Revenue
Net revenues	626	584	1,827	1,641
Neuroscience \| Botox Therapeutic \| International
Disaggregation of Revenue
Net revenues	122	115	388	350
Neuroscience \| Vraylar
Disaggregation of Revenue
Net revenues	751	554	1,970	1,473
Neuroscience \| Vraylar \| United States
Disaggregation of Revenue
Net revenues	750	554	1,967	1,473
Neuroscience \| Vraylar \| International
Disaggregation of Revenue
Net revenues	1	0	3	0
Neuroscience \| Duodopa
Disaggregation of Revenue
Net revenues	118	110	353	351
Neuroscience \| Duodopa \| United States
Disaggregation of Revenue
Net revenues	25	22	74	72
Neuroscience \| Duodopa \| International
Disaggregation of Revenue
Net revenues	93	88	279	279
Neuroscience \| Ubrelvy
Disaggregation of Revenue
Net revenues	233	160	581	483
Neuroscience \| Ubrelvy \| United States
Disaggregation of Revenue
Net revenues	230	160	574	483
Neuroscience \| Ubrelvy \| International
Disaggregation of Revenue
Net revenues	3	0	7	0
Neuroscience \| Qulipta
Disaggregation of Revenue
Net revenues	132	62	294	106
Neuroscience \| Qulipta \| United States
Disaggregation of Revenue
Net revenues	131	62	292	106
Neuroscience \| Qulipta \| International
Disaggregation of Revenue
Net revenues	1	0	2	0
Neuroscience \| Other Neuroscience
Disaggregation of Revenue
Net revenues	61	87	210	414
Neuroscience \| Other Neuroscience \| United States
Disaggregation of Revenue
Net revenues	55	82	195	400
Neuroscience \| Other Neuroscience \| International
Disaggregation of Revenue
Net revenues	6	5	15	14
Eye Care \| Ozurdex
Disaggregation of Revenue
Net revenues	120	106	354	323
Eye Care \| Ozurdex \| United States
Disaggregation of Revenue
Net revenues	34	35	107	104
Eye Care \| Ozurdex \| International
Disaggregation of Revenue
Net revenues	86	71	247	219
Eye Care \| Lumigan/Ganfort
Disaggregation of Revenue
Net revenues	91	121	340	391
Eye Care \| Lumigan/Ganfort \| United States
Disaggregation of Revenue
Net revenues	28	59	142	186
Eye Care \| Lumigan/Ganfort \| International
Disaggregation of Revenue
Net revenues	63	62	198	205
Eye Care \| Alphagan/Combigan
Disaggregation of Revenue
Net revenues	70	73	206	272
Eye Care \| Alphagan/Combigan \| United States
Disaggregation of Revenue
Net revenues	30	37	90	161
Eye Care \| Alphagan/Combigan \| International
Disaggregation of Revenue
Net revenues	40	36	116	111
Eye Care \| Restasis
Disaggregation of Revenue
Net revenues	117	142	308	556
Eye Care \| Restasis \| United States
Disaggregation of Revenue
Net revenues	104	132	265	518
Eye Care \| Restasis \| International
Disaggregation of Revenue
Net revenues	13	10	43	38
Eye Care \| Other Eye Care
Disaggregation of Revenue
Net revenues	207	181	622	569
Eye Care \| Other Eye Care \| United States
Disaggregation of Revenue
Net revenues	114	99	334	296
Eye Care \| Other Eye Care \| International
Disaggregation of Revenue
Net revenues	93	82	288	273
Other Key Products \| Mavyret
Disaggregation of Revenue
Net revenues	370	383	1,121	1,161
Other Key Products \| Mavyret \| United States
Disaggregation of Revenue
Net revenues	167	190	531	562
Other Key Products \| Mavyret \| International
Disaggregation of Revenue
Net revenues	203	193	590	599
Other Key Products \| Creon \| United States
Disaggregation of Revenue
Net revenues	305	336	892	941
Other Key Products \| Linzess/Constella
Disaggregation of Revenue
Net revenues	288	271	825	766
Other Key Products \| Linzess/Constella \| United States
Disaggregation of Revenue
Net revenues	279	262	799	742
Other Key Products \| Linzess/Constella \| International
Disaggregation of Revenue
Net revenues	$ 9	$ 9	$ 26	$ 24

Legal Proceedings and Contingencies (Details) $ in Millions	1 Months Ended	3 Months Ended			9 Months Ended
Legal Proceedings and Contingencies (Details) $ in Millions	Aug. 31, 2019 company	Sep. 30, 2023 USD ($) claim claims	Mar. 31, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) lawsuit company claim claims	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)
Legal Proceedings and Contingencies
Income tax expense		$ 172		$ 448	$ 989	$ 1,139
Niaspan
Legal Proceedings and Contingencies
Number of individual plaintiff lawsuits \| lawsuit					6
AndroGel antitrust litigation, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al.
Legal Proceedings and Contingencies
Number of generic companies with whom certain litigation related agreements were entered into \| company	3
Bystolic antitrust litigation
Legal Proceedings and Contingencies
Number of generic companies with whom certain litigation related agreements were entered into \| company					6
Prescription drug abuse litigation
Legal Proceedings and Contingencies
Number of claims pending \| claim		610			610
Prescription drug abuse litigation in state courts
Legal Proceedings and Contingencies
Number of claims pending \| claims		160			160
Prescription drug abuse litigation in state courts \| Selling, general and administrative
Legal Proceedings and Contingencies
Litigation charge related to potential settlement							$ 2,100
Tax court petition
Legal Proceedings and Contingencies
Income tax expense			$ 572

Equity

9 Months Ended

Sep. 30, 2023

Stockholders' Equity Note [Abstract]

Equity

EquityStock-Based Compensation


	Three months ended September 30,				Nine months ended September 30,
(in millions)	2023		2022		2023		2022
Cost of products sold	$	9	$	8	$	38	$	33
Research and development	53		47		227		194
Selling, general and administrative	68		71		357		312
Pre-tax compensation expense	130		126		622		539
Tax benefit	(26)		(25)		(111)		(102)
After-tax compensation expense	$	104	$	101	$	511	$	437

Stock Options

During the nine months ended September 30, 2023, primarily in connection with the company's annual grant, AbbVie granted 0.6 million stock options with a weighted-average grant-date fair value of $29.89. As of September 30, 2023, $7 million of unrecognized compensation cost related to stock options is expected to be recognized as expense over approximately the next two years.

RSUs and Performance Shares

During the nine months ended September 30, 2023, primarily in connection with the company's annual grant, AbbVie granted 5.8 million RSUs and performance shares with a weighted-average grant-date fair value of $149.59. As of September 30, 2023, $692 million of unrecognized compensation cost related to RSUs and performance shares is expected to be recognized as expense over approximately the next two years.

Cash Dividends

The following table summarizes quarterly cash dividends declared during 2023 and 2022:


2023				2022
Date Declared	Payment Date	Dividend Per Share		Date Declared	Payment Date	Dividend Per Share
10/26/23	02/15/24	$	1.55	10/28/22	02/15/23	$	1.48
09/08/23	11/15/23	$	1.48	09/09/22	11/15/22	$	1.41
06/22/23	08/15/23	$	1.48	06/23/22	08/15/22	$	1.41
02/16/23	05/15/23	$	1.48	02/17/22	05/16/22	$	1.41

Stock Repurchase Program

The company's stock repurchase authorization permits purchases of AbbVie shares from time to time in open-market or private transactions at management's discretion. The program has no time limit and can be discontinued at any time. Shares repurchased under this program are recorded at acquisition cost, including related expenses, and are available for general corporate purposes.

On February 16, 2023, AbbVie’s board of directors authorized a $5.0 billion increase to the existing stock repurchase authorization. AbbVie repurchased 10 million shares for $1.6 billion during the nine months ended September 30, 2023 and 8 million shares for $1.1 billion during the nine months ended September 30, 2022. AbbVie's remaining stock repurchase authorization was approximately $4.8 billion as of September 30, 2023.

Accumulated Other Comprehensive Loss

The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2023:


(in millions)	Foreign currency translation adjustments		Net investment hedging activities		Pension and post-employment benefits		Cash flow hedging activities		Total
Balance as of December 31, 2022	$	(1,513)	$	464	$	(1,458)	$	308	$	(2,199)
Other comprehensive income (loss) before reclassifications	(279)		156		43		61		(19)
Net gains reclassified from accumulated other comprehensive loss	—		(67)		(5)		(63)		(135)
Net current-period other comprehensive income (loss)	(279)		89		38		(2)		(154)
Balance as of September 30, 2023	$	(1,792)	$	553	$	(1,420)	$	306	$	(2,353)

Other comprehensive loss for the nine months ended September 30, 2023 included foreign currency translation adjustments totaling a loss of $279 million principally due to the impact of the weakening of the Euro on the translation of the company’s Euro-denominated assets and the offsetting impact of net investment hedging activities totaling a gain of $89 million.

The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2022:


(in millions)	Foreign currency translation adjustments		Net investment hedging activities		Pension and post-employment benefits		Cash flow hedging activities		Total
Balance as of December 31, 2021	$	(570)	$	(91)	$	(2,546)	$	308	$	(2,899)
Other comprehensive income (loss) before reclassifications	(2,043)		1,318		6		151		(568)
Net losses (gains) reclassified from accumulated other comprehensive loss	—		(53)		130		(53)		24
Net current-period other comprehensive income (loss)	(2,043)		1,265		136		98		(544)
Balance as of September 30, 2022	$	(2,613)	$	1,174	$	(2,410)	$	406	$	(3,443)

Other comprehensive loss for the nine months ended September 30, 2022 included foreign currency translation adjustments totaling a loss of $2.0 billion principally due to the impact of the weakening of the Euro on the translation of the company’s Euro-denominated assets and the offsetting impact of net investment hedging activities totaling a gain of $1.3 billion.

The following table presents the impact on AbbVie’s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss:


	Three months ended September 30,				Nine months ended September 30,
(in millions) (brackets denote gains)	2023		2022		2023		2022
Net investment hedging activities
Gains on derivative amount excluded from effectiveness testing(a)	$	(28)	$	(29)	$	(85)	$	(67)
Tax expense	6		6		18		14
Total reclassifications, net of tax	$	(22)	$	(23)	$	(67)	$	(53)
Pension and post-employment benefits
Amortization of actuarial losses and other(b)	$	(2)	$	55	$	(5)	$	166
Tax benefit	—		(12)		—		(36)
Total reclassifications, net of tax	$	(2)	$	43	$	(5)	$	130
Cash flow hedging activities
Gains on foreign currency forward exchange contracts(c)	$	(11)	$	(21)	$	(67)	$	(47)
Gains on treasury rate lock agreements(a)	(6)		(6)		(18)		(18)
Losses on cross-currency swap contracts(d)	14		—		6		—
Losses on interest rate swap contracts(a)	—		—		—		3
Tax expense	2		4		16		9
Total reclassifications, net of tax	$	(1)	$	(23)	$	(63)	$	(53)

(a) Amounts are included in interest expense, net (see Note 8).

(b) Amounts are included in the computation of net periodic benefit cost (see Note 9).

(d) Amounts are included in net foreign exchange loss (see Note 8).

Goodwill and Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of changes in the carrying amount of goodwill

The following table summarizes the changes in the carrying amount of goodwill:


(in millions)
Balance as of December 31, 2022	$	32,156
Foreign currency translation adjustments	(65)
Balance as of September 30, 2023	$	32,091

Summary of definite-lived intangible assets

The following table summarizes intangible assets:


	September 30, 2023						December 31, 2022
(in millions)	Gross carrying amount		Accumulated amortization		Net carrying amount		Gross carrying amount		Accumulated amortization		Net carrying amount
Definite-lived intangible assets
Developed product rights	$	76,526	$	(21,170)	$	55,356	$	87,698	$	(25,003)	$	62,695
License agreements	8,261		(5,299)		2,962		8,474		(4,642)		3,832
Total definite-lived intangible assets	84,787		(26,469)		58,318		96,172		(29,645)		66,527
Indefinite-lived intangible assets	285		—		285		912		—		912
Total intangible assets, net	$	85,072	$	(26,469)	$	58,603	$	97,084	$	(29,645)	$	67,439

Summary of indefinite-lived intangible assets

The following table summarizes intangible assets:


	September 30, 2023						December 31, 2022
(in millions)	Gross carrying amount		Accumulated amortization		Net carrying amount		Gross carrying amount		Accumulated amortization		Net carrying amount
Definite-lived intangible assets
Developed product rights	$	76,526	$	(21,170)	$	55,356	$	87,698	$	(25,003)	$	62,695
License agreements	8,261		(5,299)		2,962		8,474		(4,642)		3,832
Total definite-lived intangible assets	84,787		(26,469)		58,318		96,172		(29,645)		66,527
Indefinite-lived intangible assets	285		—		285		912		—		912
Total intangible assets, net	$	85,072	$	(26,469)	$	58,603	$	97,084	$	(29,645)	$	67,439

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-2

+ Details

Financial Instruments and Fair Value Measures - Bases Used To Measure The Approximate Fair Values Of Financial Instruments (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Liabilities
Carrying amount of investments in equity securities that do not have readily determinable fair values	$ 131	$ 129
Quoted prices in active markets for identical assets (Level 1)
Liabilities
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	4,763	3,930
Long-term debt and finance lease obligations, excluding fair value hedges	49,124	53,365
Total liabilities	53,887	57,295
Book value
Liabilities
Short-term borrowings	2	1
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	5,113	4,152
Long-term debt and finance lease obligations, excluding fair value hedges	56,035	59,463
Total liabilities	61,150	63,616
Approximate fair value
Liabilities
Short-term borrowings	2	1
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	5,041	4,121
Long-term debt and finance lease obligations, excluding fair value hedges	49,633	54,073
Total liabilities	54,676	58,195
Approximate fair value \| Quoted prices in active markets for identical assets (Level 1)
Liabilities
Short-term borrowings	0	0
Approximate fair value \| Significant other observable inputs (Level 2)
Liabilities
Short-term borrowings	2	1
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	278	191
Long-term debt and finance lease obligations, excluding fair value hedges	509	708
Total liabilities	789	900
Approximate fair value \| Significant unobservable inputs (Level 3)
Liabilities
Short-term borrowings	0	0
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	0	0
Long-term debt and finance lease obligations, excluding fair value hedges	0	0
Total liabilities	$ 0	$ 0

Integration and Restructuring Plans (Tables)

9 Months Ended

Sep. 30, 2023

Allergan integration plan

Restructuring charges

Summary of charges associated with integration plan

The following table summarizes the charges (benefits) associated with the Allergan acquisition integration plan:


	Three months ended September 30,				Nine months ended September 30,
(in millions)	2023		2022		2023		2022
Cost of products sold	$	20	$	24	$	66	$	81
Research and development	1		4		2		14
Selling, general and administrative	39		88		134		234
Total charges	$	60	$	116	$	202	$	329

Summary of cash activity in the restructuring reserve

The following table summarizes the cash activity in the recorded liability associated with the Allergan integration plan for the nine months ended September 30, 2023:


(in millions)
Accrued balance as of December 31, 2022	$	107
Charges	192
Payments and other adjustments	(258)
Accrued balance as of September 30, 2023	$	41

Other restructuring

Restructuring charges

Summary of cash activity in the restructuring reserve

The following table summarizes the cash activity in the restructuring reserve for the nine months ended September 30, 2023:


(in millions)
Accrued balance as of December 31, 2022	$	176
Restructuring charges	31
Payments and other adjustments	(64)
Accrued balance as of September 30, 2023	$	143

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

Equity - Stock Repurchase Program (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Feb. 16, 2023
Equity, Class of Treasury Stock
Payment for shares repurchased	$ 4	$ 4	$ 1,969	$ 1,483
Remaining share repurchase authorization amount	$ 4,800		$ 4,800
December 2018 Stock Repurchase Authorization
Equity, Class of Treasury Stock
Increase to existing stock repurchase authorization					$ 5,000
Shares repurchased (in shares)			10	8
Payment for shares repurchased			$ 1,600	$ 1,100

Collaborations (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Collaborations (Details) - USD ($) $ in Millions	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Collaborative and license agreements
AbbVie's receivable from Janssen	$ 11,412		$ 11,412		$ 11,254
AbbVie's payable to Janssen	29,658		29,658		25,402
Janssen Biotech Inc. \| Collaborative arrangement
Collaborative and license agreements
Milestone payments	200		$ 200
Share of collaboration development costs responsible by Janssen (as a percent)			60.00%
Share of collaboration development costs responsible by the entity (as a percent)			40.00%
Global - AbbVie's share of other costs (included in respective line items)	59	$ 63	$ 171	$ 196
AbbVie's receivable from Janssen	253		253		295
AbbVie's payable to Janssen	308		308		$ 379
Janssen Biotech Inc. \| Collaborative arrangement \| United States
Collaborative and license agreements
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold)	316	398	925	1,210
Janssen Biotech Inc. \| Collaborative arrangement \| International
Collaborative and license agreements
International - AbbVie's share of profits (included in net revenues)	230	286	711	868
Genentech, Inc. \| Collaborative arrangement
Collaborative and license agreements
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold)	225	204	641	578
AbbVie's share of development costs (included in R&D)	24	29	82	87
Genentech, Inc. \| Collaborative arrangement \| United States
Collaborative and license agreements
AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A)	$ 13	$ 10	$ 32	$ 27

Equity - Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax
Beginning balance	$ 12,898	$ 14,688	$ 17,287	$ 15,436
Other comprehensive loss	(101)	(247)	(154)	(544)
Ending balance	12,129	16,027	12,129	16,027
Foreign currency translation adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax
Beginning balance			(1,513)	(570)
Other comprehensive income (loss) before reclassifications			(279)	(2,043)
Net gains reclassified from accumulated other comprehensive loss			0	0
Other comprehensive loss			(279)	(2,043)
Ending balance	(1,792)	(2,613)	(1,792)	(2,613)
Net investment hedging activities
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax
Beginning balance			464	(91)
Other comprehensive income (loss) before reclassifications			156	1,318
Net gains reclassified from accumulated other comprehensive loss			(67)	(53)
Other comprehensive loss			89	1,265
Ending balance	553	1,174	553	1,174
Pension and post-employment benefits
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax
Beginning balance			(1,458)	(2,546)
Other comprehensive income (loss) before reclassifications			43	6
Net gains reclassified from accumulated other comprehensive loss	(2)	43	(5)	130
Other comprehensive loss			38	136
Ending balance	(1,420)	(2,410)	(1,420)	(2,410)
Cash flow hedging activities
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax
Beginning balance			308	308
Other comprehensive income (loss) before reclassifications			61	151
Net gains reclassified from accumulated other comprehensive loss			(63)	(53)
Other comprehensive loss			(2)	98
Ending balance	306	406	306	406
Accumulated other comprehensive income (loss)
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax
Beginning balance			(2,199)	(2,899)
Other comprehensive income (loss) before reclassifications			(19)	(568)
Net gains reclassified from accumulated other comprehensive loss			(135)	24
Other comprehensive loss			(154)	(544)
Ending balance	$ (2,353)	$ (3,443)	$ (2,353)	$ (3,443)

Financial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Into or Out of Level 3 of the Fair Value Hierarchy (Details) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Transfers of assets or liabilities between the fair value measurement levels
Transfers of assets into Level 3 of the fair value hierarchy	$ 0
Transfers of assets out of Level 3 of the fair value hierarchy	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net [Abstract]
Transfers of liabilities into Level 3 of the fair value hierarchy	0
Transfers of liabilities out of Level 3 of the fair value hierarchy	0
Reconciliation of the fair value measurements that use significant unobservable inputs (Level 3)
Beginning balance	16,384,000,000	$ 14,887,000,000
Change in fair value recognized in net earnings	3,432,000,000	647,000,000
Payments	(1,142,000,000)	(978,000,000)
Ending balance	$ 18,674,000,000	$ 14,556,000,000

Supplemental Financial Information (Tables)

9 Months Ended

Sep. 30, 2023

Supplemental Financial Information

Schedule of interest expense, net

Interest Expense, Net


	Three months ended September 30,				Nine months ended September 30,
(in millions)	2023		2022		2023		2022
Interest expense	$	555	$	560	$	1,660	$	1,664
Interest income	(157)		(63)		(354)		(96)
Interest expense, net	$	398	$	497	$	1,306	$	1,568

Schedule of inventories

Inventories


(in millions)	September 30, 2023		December 31, 2022
Finished goods	$	1,035	$	1,162
Work-in-process	1,690		1,417
Raw materials	1,256		1,000
Inventories	$	3,981	$	3,579

Schedule of property and equipment, net

Property and Equipment, Net


(in millions)	September 30, 2023		December 31, 2022
Property and equipment, gross	$	11,374	$	10,986
Accumulated depreciation	(6,440)		(6,051)
Property and equipment, net	$	4,934	$	4,935

Financial Instruments and Fair Value Measures - Concentrations of Risk (Details) - wholesaler	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Accounts receivable, net
Concentration of Risk
Number of principal customers	3
Accounts receivable, net \| Geographic risk \| Principal US customers
Concentration of Risk
Concentrations risk (as a percent)	81.00%		82.00%
Total revenues \| HUMIRA \| Humira
Concentration of Risk
Concentrations risk (as a percent)	28.00%	36.00%

Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Other Comprehensive Income (Loss), Tax, Parenthetical Disclosures [Abstract]
Foreign currency translation adjustments, tax expense (benefit)	$ (17)	$ (11)	$ (11)	$ (30)
Net investment hedging activities, tax expense (benefit)	84	165	26	348
Pension and post-employment benefits, tax expense (benefit)	1	14	11	35
Cash flow hedging activities, tax expense (benefit)	$ 7	$ 14	$ (1)	$ 17

Financial Instruments and Fair Value Measures - Amount Of Gain/(Loss) Recognized For Derivative Instruments (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Gain (loss) on derivatives
Foreign currency contracts	$ 531		$ 531		$ 524
Cost of products sold
Gain (loss) on derivatives
Pre-tax gains (losses) to be transferred into cost of products sold for foreign currency cash flow hedges during the next 12 months	74		74
Net foreign exchange loss
Gain (loss) on derivatives
Pre-tax gains (losses) to be transferred into net foreign exchange gain/loss for cross-currency swap contract cash flow hedges during the next 12 months	1		1
Interest expense, net
Gain (loss) on derivatives
Pre-tax gains (losses) to be transferred into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months	24		24
Interest expense, net \| Fair value hedges
Gain (loss) on derivatives
Debt designated as hedged item in fair value hedges gain (loss) recognized in the consolidated statements of earnings	58	$ 141	44	$ 424
Designated as hedging instrument \| Senior notes
Gain (loss) on derivatives
Pre-tax gains (losses) from net investment hedge instruments recognized in other comprehensive income	173	431	47	932
Foreign currency forward exchange contracts \| Designated as hedging instrument
Gain (loss) on derivatives
Pre-tax gains (losses) from cash flow hedges recognized in other comprehensive income	76	124	81	171
Pre-tax gains (losses) from net investment hedge instruments recognized in other comprehensive income	241	362	153	748
Foreign currency forward exchange contracts \| Designated as hedging instrument \| Cash flow hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidate statements of earnings	$ 11	21	$ 67	$ 47
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of products sold		Cost of products sold	Cost of products sold
Foreign currency forward exchange contracts \| Designated as hedging instrument \| Net investment hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidate statements of earnings	$ 28	$ 29	$ 85	$ 67
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Interest Income (Expense), Nonoperating, Net	Interest Income (Expense), Nonoperating, Net	Interest Income (Expense), Nonoperating, Net	Interest Income (Expense), Nonoperating, Net
Foreign currency forward exchange contracts \| Not designated as hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidate statements of earnings	$ (41)	$ (121)	$ (7)	$ (285)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Unrealized Gain (Loss), Foreign Currency Transaction, before Tax	Unrealized Gain (Loss), Foreign Currency Transaction, before Tax	Unrealized Gain (Loss), Foreign Currency Transaction, before Tax	Unrealized Gain (Loss), Foreign Currency Transaction, before Tax
Treasury rate lock agreements \| Designated as hedging instrument \| Cash flow hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidate statements of earnings	$ 6	$ 6	$ 18	$ 18
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Interest Income (Expense), Nonoperating, Net	Interest Income (Expense), Nonoperating, Net	Interest Income (Expense), Nonoperating, Net	Interest Income (Expense), Nonoperating, Net
Cross-currency swap contracts \| Designated as hedging instrument
Gain (loss) on derivatives
Pre-tax gains (losses) from cash flow hedges recognized in other comprehensive income	$ (14)	$ 0	$ (5)	$ 0
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Unrealized Gain (Loss), Foreign Currency Transaction, before Tax	Unrealized Gain (Loss), Foreign Currency Transaction, before Tax	Unrealized Gain (Loss), Foreign Currency Transaction, before Tax	Unrealized Gain (Loss), Foreign Currency Transaction, before Tax
Cross-currency swap contracts \| Designated as hedging instrument \| Cash flow hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidate statements of earnings	$ (14)	$ 0	$ (6)	$ 0
Interest rate swap contracts \| Designated as hedging instrument
Gain (loss) on derivatives
Pre-tax gains (losses) from cash flow hedges recognized in other comprehensive income	0	0	0	6
Interest rate swap contracts \| Designated as hedging instrument \| Cash flow hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidate statements of earnings	$ 0	$ 0	$ 0	$ (3)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Interest Income (Expense), Nonoperating, Net	Interest Income (Expense), Nonoperating, Net	Interest Income (Expense), Nonoperating, Net	Interest Income (Expense), Nonoperating, Net
Interest rate swap contracts \| Designated as hedging instrument \| Fair value hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidate statements of earnings	$ (58)	$ (141)	$ (44)	$ (424)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Interest Income (Expense), Nonoperating, Net	Interest Income (Expense), Nonoperating, Net	Interest Income (Expense), Nonoperating, Net	Interest Income (Expense), Nonoperating, Net
Cross-currency swap contracts \| Fair Value, Recurring
Gain (loss) on derivatives
Foreign currency contracts	$ 5		$ 5
Cross-currency swap contracts \| Significant other observable inputs (Level 2) \| Fair Value, Recurring
Gain (loss) on derivatives
Foreign currency contracts	5		5
Cross-currency swap contracts \| Quoted prices in active markets for identical assets (Level 1) \| Fair Value, Recurring
Gain (loss) on derivatives
Foreign currency contracts	0		0
Cross-currency swap contracts \| Significant unobservable inputs (Level 3) \| Fair Value, Recurring
Gain (loss) on derivatives
Foreign currency contracts	$ 0		$ 0

Goodwill and Intangible Assets

9 Months Ended

Sep. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

Goodwill and Intangible AssetsGoodwill

The following table summarizes the changes in the carrying amount of goodwill:


(in millions)
Balance as of December 31, 2022	$	32,156
Foreign currency translation adjustments	(65)
Balance as of September 30, 2023	$	32,091

The company performs its annual goodwill impairment assessment in the third quarter, or earlier if impairment indicators exist. As of September 30, 2023, there were no accumulated goodwill impairment losses.

Intangible Assets, Net

The following table summarizes intangible assets:


	September 30, 2023						December 31, 2022
(in millions)	Gross carrying amount		Accumulated amortization		Net carrying amount		Gross carrying amount		Accumulated amortization		Net carrying amount
Definite-lived intangible assets
Developed product rights	$	76,526	$	(21,170)	$	55,356	$	87,698	$	(25,003)	$	62,695
License agreements	8,261		(5,299)		2,962		8,474		(4,642)		3,832
Total definite-lived intangible assets	84,787		(26,469)		58,318		96,172		(29,645)		66,527
Indefinite-lived intangible assets	285		—		285		912		—		912
Total intangible assets, net	$	85,072	$	(26,469)	$	58,603	$	97,084	$	(29,645)	$	67,439

Definite-Lived Intangible Assets

Amortization expense was $2.0 billion for the three months and $6.1 billion for the nine months ended September 30, 2023 and $2.0 billion for the three months and $5.7 billion for the nine months ended September 30, 2022. Amortization expense was included in cost of products sold in the condensed consolidated statements of earnings.

In August 2023, as part of the Inflation Reduction Act (IRA) of 2022, the company’s oncology product Imbruvica sold in the United States (U.S.) was included on the list of products selected for negotiation by the Centers for Medicare & Medicaid Services. The selection resulted in a significant decrease in the estimated future cash flows for the product and represented a triggering event

which required the company to evaluate the underlying definite lived-intangible asset for impairment. The company utilized a discounted cash flow analysis to determine the fair value of $1.9 billion, which was lower than the carrying value of $4.0 billion and resulted in a partial impairment of both the gross and net carrying amount as of August 29, 2023. Based on the revised cash flows, the company recorded a pre-tax impairment charge of $2.1 billion to cost of products sold in the condensed consolidated statement of earnings for the third quarter of 2023. The fair value measurement was based on Level 3 inputs including estimated net revenues, cost of products sold, R&D costs, selling and marketing costs and discount rate. The remaining intangible asset carrying value related to Imbruvica in the U.S. totaled $1.8 billion as of September 30, 2023.

In September 2022, the company made a strategic decision to reduce ongoing sales and marketing investment related to Vuity, an on-market product to treat presbyopia. This strategic decision contributed to a significant decrease in the estimated future cash flows for the product and represented a triggering event which required the company to evaluate the underlying definite lived-intangible asset for impairment. The company utilized a discounted cash flow analysis to estimate the fair value of the intangible asset resulting in a full impairment of both the gross and net carrying amount. Based on the revised cash flows, the company recorded a pre-tax impairment charge of $770 million to cost of products sold in the condensed consolidated statement of earnings for the third quarter of 2022.

Indefinite-Lived Intangible Assets

Indefinite-lived intangible assets represent acquired IPR&D associated with products that have not yet received regulatory approval. The company performs its annual impairment assessment of indefinite-lived intangible assets in the third quarter, or earlier if impairment indicators exist.

During the first quarter of 2023, the company made a decision to revise the research and development plan for AGN-151607, a novel investigational neurotoxin for the prevention of postoperative atrial fibrillation in cardiac surgery patients. This decision contributed to a delay in the estimated timing of regulatory approval as well as a significant decrease in estimated future cash flows of the product and represented a triggering event which required the company to evaluate the underlying indefinite-lived intangible asset for impairment. The company utilized a discounted cash flow analysis to estimate the fair value which was below the carrying value of the intangible asset. Based on the revised cash flows, the company recorded a pre-tax impairment charge of $630 million to research and development expense in the condensed consolidated statement of earnings for the first quarter of 2023.

Licensing, Acquisitions and Other Arrangements (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Feb. 28, 2022
Collaborative and license agreements
Cash outflows related to acquisitions and investments				$ (670)	$ (494)
Acquired IPR&D and milestones	$ 66	$ 40		496	454
Gain on divestitures					172
Collaborative arrangement
Collaborative and license agreements
Research and development milestone expenses	22	0		100	62
Syndesi \| Collaborative arrangement
Collaborative and license agreements
Acquired IPR&D and milestones		130
Syndesi \| Collaborative arrangement \| Maximum
Collaborative and license agreements
Potential payments under agreement certain milestones						$ 870
Juvise Pharmaceuticals \| Other operating income (expense)
Collaborative and license agreements
Gain on divestitures			$ 172
Juvise Pharmaceuticals \| Collaborative arrangement
Collaborative and license agreements
Proceeds from sale of assets			$ 215
Other Collaboration Arrangements \| Collaborative arrangement
Collaborative and license agreements
Acquired IPR&D and milestones	$ 44	$ 40		$ 396	$ 262

Equity - Cash Dividends (Details) - $ / shares	Oct. 26, 2023	Sep. 08, 2023	Jun. 22, 2023	Feb. 16, 2023	Oct. 28, 2022	Sep. 09, 2022	Jun. 23, 2022	Feb. 17, 2022
Subsequent event
Dividends Payable
Cash dividends declared per common share (in dollars per share)	$ 1.55
Dividend Declared [Member]
Dividends Payable
Cash dividends declared per common share (in dollars per share)		$ 1.48	$ 1.48	$ 1.48	$ 1.48	$ 1.41	$ 1.41	$ 1.41